[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 217
1. Nicolas MM, Nayar R, Yeldandi A, De Frias DV: Pulmonary metastasis of a postradiation breast epithelioid angiosarcoma mimicking adenocarcinoma. A case report. Acta Cytol; 2006 Nov-Dec;50(6):672-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary metastasis of a postradiation breast epithelioid angiosarcoma mimicking adenocarcinoma. A case report.
  • We report a case of metastatic postradiation EAS to the lungs that was mistaken for adenocarcinoma.
  • CASE: A 45-year-old woman who received radiotherapy for ductal carcinoma in situ (DCIS) 5 years previously had a local recurrence a year earlier and recent development of bilateral small pulmonary nodules.
  • An interpretation of adenocarcinoma was rendered during assessment for specimen adequacy.
  • The original breast tumor was typical of cribriform DCIS.
  • Review of the recurrent breast tumor (initially reported as DCIS) and a prior wedge resection of the lung nodules (reported as EAS) showed an epithelial-appearing tumor exhibiting an endothelial immunophenotype CONCLUSION: The cytologic features of EAS may resemble those of other neoplasms.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / radiotherapy. Hemangiosarcoma / secondary. Lung Neoplasms / secondary. Neoplasms, Radiation-Induced / pathology. Radiotherapy / adverse effects
  • [MeSH-minor] Biopsy, Fine-Needle / methods. Diagnosis, Differential. Epithelioid Cells / pathology. Female. Humans. Middle Aged


2. de Candia P, Akram M, Benezra R, Brogi E: Id4 messenger RNA and estrogen receptor expression: inverse correlation in human normal breast epithelium and carcinoma. Hum Pathol; 2006 Aug;37(8):1032-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Id4 messenger RNA and estrogen receptor expression: inverse correlation in human normal breast epithelium and carcinoma.
  • We assessed the expression of Id4 messenger RNA (mRNA) in invasive mammary carcinoma from 31 patients, as well as in 21 cases of ductal carcinoma in situ, in 9 lymph node metastases, and in the morphologically normal epithelium adjacent to the carcinoma from the same subjects.
  • In addition, we evaluated Id4 mRNA in atypical ductal hyperplasia from 5 other women and in normal breast tissue from yet another 5 women with no history of breast malignancy or atypia.
  • Id4 mRNA was present in the normal ER-negative mammary epithelium in all cases; in contrast, the ER-positive cells present in the normal breast were Id4 negative.
  • Id4 mRNA was not detected in atypical ductal hyperplasia, in 22 of the 23 cases of ductal carcinoma in situ, and in 27 of the 31 invasive carcinomas (P = .0008), all of which were ER positive.
  • Our data show that Id4 is constitutively expressed in the normal human mammary epithelium but is suppressed in ER-positive breast carcinomas and preneoplastic lesions.
  • These results support a possible role of Id4 as a tumor suppressor factor in the human breast and suggest that the expression of Id4 in the mammary ductal epithelium may be regulated by estrogen.
  • Further investigations are required to define the functions of Id4 in the human normal breast and in mammary neoplasia.
  • [MeSH-major] Adenocarcinoma / genetics. Breast Neoplasms / genetics. Helix-Loop-Helix Motifs. Inhibitor of Differentiation Proteins / genetics. RNA, Messenger / metabolism. Receptors, Estrogen / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast / cytology. Breast / metabolism. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / secondary. Carcinoma, Intraductal, Noninfiltrating / genetics. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / genetics. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / secondary. Epithelial Cells / cytology. Epithelial Cells / metabolism. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization. Middle Aged. Neoplasm Staging. RNA, Neoplasm / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16867866.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ID4 protein, human; 0 / Inhibitor of Differentiation Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Receptors, Estrogen
  •  go-up   go-down


3. Kumar N, Bongiovanni M, Molliet MJ, Pelte MF, Egger JF, Pache JC: Diverse glandular pathologies coexist with high-grade squamous intraepithelial lesion in cyto-histological review of atypical glandular cells on ThinPrep specimens. Cytopathology; 2009 Dec;20(6):351-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Thirty-nine ThinPrep cervical smear (Pap) tests reported as AGC of undetermined significance and showing high-grade lesions on histology [cervical intraepithelial neoplasia (CIN) 2 or 3, endometrial or extrauterine adenocarcinoma] were reviewed retrospectively to identify the cases of high-grade squamous intraepithelial lesion with endocervical glandular extension, using the Bethesda 2001 system.
  • This included endocervical glandular extension in 63%, benign glandular pathology in 33% and pre-neoplastic or malignant glandular pathology (endocervical glandular dysplasia, adenocarcinoma in situ and metastatic breast carcinoma) in 17% cases.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Precancerous Conditions / diagnosis. Precancerous Conditions / pathology. Retrospective Studies. Sensitivity and Specificity. Young Adult


Advertisement
4. Han B, Mehra R, Suleman K, Tomlins SA, Wang L, Singhal N, Linetzky KA, Palanisamy N, Zhou M, Chinnaiyan AM, Shah RB: Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma. Mod Pathol; 2009 Sep;22(9):1176-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we used break-apart fluorescence in situ hybridization to assess TMPRSS2 and ETS aberrations in a series of select histologic variants: foamy gland carcinoma (N=17), ductal adenocarcinoma (N=18), mucinous carcinoma (N=18), and small cell carcinoma (N=7).
  • A histologic variation of acinar adenocarcinoma, demonstrating glomeruloid morphology (N=9), was also investigated.
  • SPINK1, a biomarker expressed exclusively in a subset of ETS negative prostate carcinomas, was expressed in 6% of ETS negative histologic variants, specifically in ductal adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast Cancer Res. 1999;1(1):31-5 [11250680.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8337-41 [16951139.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Jun;40(2):152-7 [15101049.001]
  • [Cites] Mod Pathol. 2004 Mar;17(3):316-27 [14976541.001]
  • [Cites] Blood. 1996 Oct 1;88(7):2375-84 [8839828.001]
  • [Cites] Mod Pathol. 1997 Jun;10(6):612-29 [9195581.001]
  • [Cites] Int J Exp Pathol. 2005 Aug;86(4):213-8 [16045543.001]
  • [Cites] Science. 2005 Oct 28;310(5748):644-8 [16254181.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3396-400 [16585160.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10242-6 [17079440.001]
  • [Cites] Nat Genet. 2007 Jan;39(1):41-51 [17173048.001]
  • [Cites] Neoplasia. 2007 Mar;9(3):200-6 [17401460.001]
  • [Cites] Mod Pathol. 2007 May;20(5):538-44 [17334343.001]
  • [Cites] J Pathol. 2007 May;212(1):91-101 [17385188.001]
  • [Cites] Am J Surg Pathol. 2007 Jun;31(6):882-8 [17527075.001]
  • [Cites] J Clin Pathol. 2007 Jul;60(7):781-6 [16901974.001]
  • [Cites] Oncogene. 2007 Jul 5;26(31):4596-9 [17237811.001]
  • [Cites] Nature. 2007 Aug 2;448(7153):595-9 [17671502.001]
  • [Cites] Mod Pathol. 2007 Sep;20(9):921-8 [17632455.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):7991-5 [17804708.001]
  • [Cites] J Clin Pathol. 2007 Nov;60(11):1238-43 [17259299.001]
  • [Cites] Urology. 2007 Oct;70(4):630-3 [17991527.001]
  • [Cites] Br J Cancer. 2007 Dec 17;97(12):1690-5 [17971772.001]
  • [Cites] Cancer Res. 2008 Jan 1;68(1):73-80 [18172298.001]
  • [Cites] Oncogene. 2008 Jan 10;27(3):253-63 [17637754.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3094-8 [18451133.001]
  • [Cites] Cancer Res. 2008 May 15;68(10):3584-90 [18483239.001]
  • [Cites] Cancer Cell. 2008 Jun;13(6):519-28 [18538735.001]
  • [Cites] Cancer Res. 2008 Sep 15;68(18):7629-37 [18794152.001]
  • [Cites] Cancer Metastasis Rev. 2002;21(3-4):381-95 [12549773.001]
  • (PMID = 19465903.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA069568-110020; United States / NCI NIH HHS / CA / U01 CA111275-01; United States / NCI NIH HHS / CA / R01 CA102872; United States / NCI NIH HHS / CA / P50CA69568; United States / NCI NIH HHS / CA / CA069568-110020; United States / NCI NIH HHS / CA / UO1 CA111275-01; United States / NCI NIH HHS / CA / P50 CA069568; United States / NCI NIH HHS / CA / U01 CA111275
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Proteins c-ets; 0 / SPINK1 protein, human; 0 / TMPRSS2-ERG fusion protein, human; 0 / TMPRSS2-ETV1 fusion protein, human
  • [Other-IDs] NLM/ NIHMS148618; NLM/ PMC2760291
  •  go-up   go-down


5. Yu J, Bhargava R, Dabbs DJ: Invasive lobular carcinoma with extracellular mucin production and HER-2 overexpression: a case report and further case studies. Diagn Pathol; 2010;5:36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Invasive lobular carcinomas (ILC) of breast typically demonstrate intracytoplasmic mucin.
  • We present a unique case of classical type ILC with abundant extracellular mucin and strong ERBB2 (HER2/neu) expression confirmed by immunohistochemistry and fluorescent in situ hybridization.
  • In addition, studies of tissue microarrays of 80 breast carcinomas with mucinous differentiation revealed 4 pure mucinous carcinomas showing significantly reduced E-cadherin staining without redistribution of p120 into cytoplasm.
  • The findings suggest that the presence of extracellular mucin does not exclude a diagnosis of lobular carcinoma, and the morphologic and molecular characteristics of lobular and ductal carcinomas are more complex than previously appreciated.
  • [MeSH-major] Adenocarcinoma, Mucinous / chemistry. Biomarkers, Tumor / analysis. Breast Neoplasms / chemistry. Carcinoma, Lobular / chemistry. Mucin-1 / analysis. Receptor, ErbB-2 / analysis
  • [MeSH-minor] Aged. Biopsy. Cadherins / analysis. Catenins / analysis. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Mastectomy, Segmental. Neoplasm Invasiveness. Tissue Array Analysis. Up-Regulation


6. Chen DB, Kan X: [Cystic hypersecretory carcinoma with microinvasive carcinoma and cystic hypersecretory hyperplasia of breast: report of a case]. Zhonghua Bing Li Xue Za Zhi; 2010 Jan;39(1):54-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cystic hypersecretory carcinoma with microinvasive carcinoma and cystic hypersecretory hyperplasia of breast: report of a case].
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma in Situ / pathology. Carcinoma, Ductal, Breast / pathology. Fibrocystic Breast Disease / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adult. Carcinoma / pathology. Diagnosis, Differential. Female. Humans. Hyperplasia. Lactalbumin / metabolism. S100 Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20388402.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / S100 Proteins; 9013-90-5 / Lactalbumin; Secretory breast carcinoma
  •  go-up   go-down


7. Kazakov DV, Requena L, Kutzner H, Fernandez-Figueras MT, Kacerovska D, Mentzel T, Schwabbauer P, Michal M: Morphologic diversity of syringocystadenocarcinoma papilliferum based on a clinicopathologic study of 6 cases and review of the literature. Am J Dermatopathol; 2010 Jun;32(4):340-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Syringocystadenocarcinoma papilliferum invariably occurred in association with syringocystadenoma papilliferum and presented as an in situ adenocarcinoma and/or invasive adenocarcinoma.
  • Variable present features included pagetoid migration of the neoplastic cells, dirty necrosis, mucinous ductal metaplasia, and ductal changes analogous to those seen in the breast.
  • The ductal changes included patterns identical to columnar cell change (flat epithelial atypia), usual ductal hyperplasia, atypical ductal hyperplasia, and ductal carcinoma in situ.
  • Its association with the benign counterpart and ductal changes suggests a transformation that may involve usual ductal hyperplasia-atypical ductal hyperplasia-(ductal) adenocarcinoma in situ-invasive adenocarcinoma pathway.
  • [MeSH-minor] Adenoma, Sweat Gland / pathology. Aged. Aged, 80 and over. Carcinoma in Situ / pathology. Carcinoma, Ductal / pathology. Carcinoma, Squamous Cell / pathology. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20216201.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 25
  •  go-up   go-down


8. Chu QD, Sun L, Li J, Byrnes K, Chervenak D, DeBenedetti A, Mathis JM, Li BD: Rat adenocarcinoma cell line infected with an adenovirus carrying a novel herpes-simplex virus-thymidine kinase suicide gene construct dies by apoptosis upon treatment with ganciclovir. J Surg Res; 2007 Nov;143(1):189-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rat adenocarcinoma cell line infected with an adenovirus carrying a novel herpes-simplex virus-thymidine kinase suicide gene construct dies by apoptosis upon treatment with ganciclovir.
  • This protein has been found in elevated quantities in breast, colon, and head and neck cancers.
  • In this study, we investigated the in vitro activity of this suicide gene therapy against the rat Mat BIII breast adenocarcinoma cell line, and assessed whether apoptosis was the responsible mechanism of cell killing.
  • Induction of apoptosis was determined using annexin V-FITC and propidium iodine detection kit and a terminal deoxynucleotidyl transferase biotin-dUTP nick end labeling in situ cell death detection kit.
  • CONCLUSION: Suicide gene therapy targeting the overexpression of eIF4E induces apoptosis and cell death in rat Mat BIII mammary adenocarcinoma cells.
  • [MeSH-major] Adenocarcinoma / therapy. Apoptosis / drug effects. Eukaryotic Initiation Factor-4E / metabolism. Ganciclovir / pharmacology. Genes, Transgenic, Suicide. Mammary Neoplasms, Animal / therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GANCICLOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17950092.001).
  • [ISSN] 0022-4804
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Eukaryotic Initiation Factor-4E; 0 / Fluorescent Dyes; EC 2.7.1.21 / Thymidine Kinase; I223NX31W9 / Fluorescein-5-isothiocyanate; P9G3CKZ4P5 / Ganciclovir
  •  go-up   go-down


9. Hemminki K, Granström C, Chen B: The Swedish family-cancer database: update, application to colorectal cancer and clinical relevance. Hered Cancer Clin Pract; 2005;3(1):7-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cancer cases were retrieved from the Swedish Cancer Registry from 1958-2002, including over 1.2 million first and multiple primary cancers and in situ tumours.
  • Compared to previous versions, only 6.0% of deceased offspring with a cancer diagnosis lack any parental information.
  • We show one application of the Database in the study of familial risks in colorectal adenocarcinoma, with defined age-group and anatomic site specific analyses.
  • Useful risk estimates have been developed for familial breast and prostate cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2004 Jan 20;108(3):433-42 [14648711.001]
  • [Cites] Br J Cancer. 2001 Apr 6;84(7):969-74 [11286479.001]
  • [Cites] Int J Cancer. 2004 Jan 1;108(1):109-14 [14618624.001]
  • [Cites] Fam Cancer. 2003;2(2):87-93 [14574157.001]
  • [Cites] Am J Pathol. 2003 Sep;163(3):827-32 [12937124.001]
  • [Cites] Lancet. 2003 Jul 5;362(9377):39-41 [12853198.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1769-71 [12702560.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):919-32 [12621137.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1638-44 [12496055.001]
  • [Cites] Cancer. 2003 Jan 1;97(1 Suppl):230-5 [12491486.001]
  • [Cites] Eur J Cancer. 2002 Dec;38(18):2428-34 [12460788.001]
  • [Cites] Int J Cancer. 2003 Jan 1;103(1):105-9 [12455061.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1332-52 [12433710.001]
  • [Cites] Science. 2002 Sep 20;297(5589):2013 [12242432.001]
  • [Cites] Int J Cancer. 2002 May 10;99(2):229-37 [11979438.001]
  • [Cites] Int J Cancer. 2002 May 10;99(2):218-28 [11979437.001]
  • [Cites] CA Cancer J Clin. 2002 Jan-Feb;52(1):8-22 [11814067.001]
  • [Cites] Nat Genet. 2002 Feb;30(2):227-32 [11818965.001]
  • [Cites] Int J Cancer. 2001 Dec 1;94(5):743-8 [11745471.001]
  • [Cites] Lancet. 2001 Oct 27;358(9291):1389-99 [11705483.001]
  • [Cites] Am J Gastroenterol. 2001 Oct;96(10):2992-3003 [11693338.001]
  • [Cites] Br J Cancer. 2001 Feb 2;84(3):388-91 [11161404.001]
  • [Cites] N Engl J Med. 2000 Jul 13;343(2):78-85 [10891514.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(11):2193-200 [10829038.001]
  • [Cites] Nat Genet. 2004 Dec;36(12):1312-8 [15543147.001]
  • [Cites] J Med Genet. 2004 Nov;41(11):801-7 [15520403.001]
  • [Cites] J Natl Cancer Inst. 1999 Jun 2;91(11):916-32 [10359544.001]
  • [Cites] Int J Oncol. 1998 Mar;12(3):701-10 [9472113.001]
  • [Cites] Nature. 1998 Jan 8;391(6663):184-7 [9428765.001]
  • [Cites] Int J Cancer. 1996 Nov 15;68(4):428-35 [8945611.001]
  • [Cites] Br Med Bull. 1994 Jul;50(3):527-35 [7987639.001]
  • [Cites] Cancer Detect Prev. 1995;19(3):219-33 [7750110.001]
  • [Cites] J Natl Cancer Inst. 1994 Nov 2;86(21):1600-8 [7932824.001]
  • [Cites] J Natl Cancer Inst. 1989 Dec 20;81(24):1879-86 [2593165.001]
  • [Cites] Am J Epidemiol. 1990 Jun;131(6):961-72 [2188501.001]
  • [Cites] Int J Cancer. 2004 Jun 10;110(2):291-4 [15069696.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3375-6 [12947078.001]
  • [Cites] Int J Cancer. 2004 Sep 20;111(5):809-10 [15252856.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jul;13(7):1253-6 [15247139.001]
  • [Cites] Stat Med. 2004 Apr 15;23(7):1111-30 [15057881.001]
  • [Cites] Int J Cancer. 2004 Apr 20;109(4):554-8 [14991577.001]
  • [Cites] J Med Genet. 2004 Feb;41(2):81-91 [14757853.001]
  • [Cites] Gastroenterology. 2001 Oct;121(4):830-8 [11606497.001]
  • [Cites] Gastroenterology. 2001 Aug;121(2):282-301 [11487538.001]
  • [Cites] J Med Genet. 2003 Nov;40(11):807-14 [14627668.001]
  • (PMID = 20223029.001).
  • [ISSN] 1897-4287
  • [Journal-full-title] Hereditary cancer in clinical practice
  • [ISO-abbreviation] Hered Cancer Clin Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Other-IDs] NLM/ PMC2837068
  •  go-up   go-down


10. Marx AH, Burandt EC, Choschzick M, Simon R, Yekebas E, Kaifi JT, Mirlacher M, Atanackovic D, Bokemeyer C, Fiedler W, Terracciano L, Sauter G, Izbicki JR: Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers. Hum Pathol; 2010 Nov;41(11):1577-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HER-2 is the molecular target for antibody-based treatment of breast cancer (trastuzumab).
  • To address the potential applicability of anti-HER-2 therapy in colorectal cancer, tissue microarray sections and colorectal resection specimens of 1851 colorectal cancers were analyzed for HER-2 overexpression and amplification using FDA approved reagents for immunohistochemistry and fluorescence in situ hybridization.
  • [MeSH-major] Adenocarcinoma / genetics. Colorectal Neoplasms / genetics. Gene Amplification / genetics. Genes, erbB-2 / genetics. Receptor, ErbB-2 / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. DNA, Neoplasm / analysis. Female. Germany / epidemiology. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Kaplan-Meier Estimate. Male. Middle Aged. Survival Rate. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20656317.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


11. Kobuya M: [Helical CT examination of the breast]. Nihon Hoshasen Gijutsu Gakkai Zasshi; 2005 Nov 20;61(11):1467-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Helical CT examination of the breast].
  • [MeSH-minor] Adenocarcinoma, Scirrhous / radiography. Breast Neoplasms / radiography. Carcinoma in Situ / radiography. Carcinoma, Ductal / radiography. Female. Humans

  • MedlinePlus Health Information. consumer health - Mammography.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16317405.001).
  • [ISSN] 0369-4305
  • [Journal-full-title] Nihon Hōshasen Gijutsu Gakkai zasshi
  • [ISO-abbreviation] Nihon Hoshasen Gijutsu Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 30
  •  go-up   go-down


12. Marx AH, Tharun L, Muth J, Dancau AM, Simon R, Yekebas E, Kaifi JT, Mirlacher M, Brümmendorf TH, Bokemeyer C, Izbicki JR, Sauter G: HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol; 2009 Jun;40(6):769-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Her-2 is the molecular target for antibody-based treatment of breast cancer (trastuzumab).
  • To address the potential applicability of trastuzumab in gastric cancer, tissue microarray sections of 166 gastric adenocarcinomas and 69 lymph node metastases were analyzed for Her-2 overexpression and amplification using Food and Drug Administration-approved reagents for immunohistochemistry and fluorescence in situ hybridization.
  • [MeSH-major] Adenocarcinoma / genetics. Genes, erbB-2 / genetics. Stomach Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antigens, Neoplasm / genetics. DNA Topoisomerases, Type II / genetics. DNA-Binding Proteins / genetics. Female. Gene Amplification. Humans. In Situ Hybridization, Fluorescence. Lymphatic Metastasis. Male. Middle Aged. Receptor, ErbB-2 / immunology. Tissue Array Analysis. Trastuzumab

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hum Pathol. 2011 Jun;42(6):909-10; author reply 910-1 [21571126.001]
  • [CommentIn] Hum Pathol. 2010 Feb;41(2):304-5; author reply 305-6 [19914678.001]
  • (PMID = 19269014.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha; P188ANX8CK / Trastuzumab
  •  go-up   go-down


13. Okines AF, Cunningham D: Trastuzumab in gastric cancer. Eur J Cancer; 2010 Jul;46(11):1949-59
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Trastuzumab is a fully humanised monoclonal antibody directed at the human epidermal growth factor receptor-2 (HER-2) which has been a component of standard therapy for advanced and resected HER-2-positive breast cancers for almost a decade.
  • HER-2 over-expression, defined as HER-2 protein over-expression using immunohistochemistry scored as 3+ and/or erbB-2 amplification detected by fluorescent in situ hybridisation, was detected in 22.1% of 3807 patients with advanced gastric and oesophagogastric junction (OGJ) adenocarcinoma screened for eligibility for the phase III ToGA study.
  • The validated scoring system for HER-2 positivity in gastric cancers differs from that recommended for breast cancer due to an increased frequency of incomplete membranous immunoreactivity and heterogeneity of HER-2 expression in gastric cancers.
  • The international multicentre randomised phase III ToGA study assessed the addition of trastuzumab to a cisplatin plus fluoropyrimidine (FP) chemotherapy doublet for patients with HER-2-positive advanced gastric or OGJ adenocarcinoma.
  • Additionally, research into mechanisms of resistance and strategies to overcome primary or acquired resistance to trastuzumab must now be expedited, using lessons learnt over the past decade in HER-2-positive breast cancer to maximise the benefit from this agent.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20542421.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Quinazolines; 0VUA21238F / lapatinib; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab
  •  go-up   go-down


14. Dziadziuszko R, Merrick DT, Witta SE, Mendoza AD, Szostakiewicz B, Szymanowska A, Rzyman W, Dziadziuszko K, Jassem J, Bunn PA Jr, Varella-Garcia M, Hirsch FR: Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression. J Clin Oncol; 2010 May 1;28(13):2174-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression.
  • IGF1R gene copy number was assessed by fluorescent in situ hybridization using customized probes (n = 181).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Squamous Cell / genetics. Gene Dosage. Gene Expression Regulation, Neoplastic. In Situ Hybridization, Fluorescence. Lung Neoplasms / genetics. Pulmonary Surgical Procedures. RNA, Messenger / analysis. Receptor, IGF Type 1 / genetics
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / genetics. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Aneuploidy. Carcinoma, Large Cell / chemistry. Carcinoma, Large Cell / genetics. Carcinoma, Large Cell / surgery. Disease-Free Survival. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Receptor, Epidermal Growth Factor / genetics. Reverse Transcriptase Polymerase Chain Reaction. Risk Assessment. Risk Factors. Time Factors. Tissue Array Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 1989 Nov;109(5):2495-507 [2553748.001]
  • [Cites] Cancer Res. 1987 Nov 15;47(22):6126-33 [3664512.001]
  • [Cites] Endocr Relat Cancer. 2004 Dec;11(4):793-814 [15613453.001]
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):643-55 [15870435.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):5900-9 [16043828.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):11118-28 [16322262.001]
  • [Cites] Thorax. 2006 Feb;61(2):140-5 [16284218.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3078-84 [16707605.001]
  • [Cites] Ann Oncol. 2006 Jul;17(7):1120-7 [16600976.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3798-807 [12953099.001]
  • [Cites] J Clin Oncol. 2009 May 20;27(15):2516-22 [19380445.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):10100-11 [17047074.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5034-42 [17075123.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2795-803 [17473213.001]
  • [Cites] J Thorac Oncol. 2007 Aug;2(8):706-14 [17762336.001]
  • [Cites] Clin Cancer Res. 2007 Oct 1;13(19):5834-40 [17908976.001]
  • [Cites] Cancer. 2008 Mar 1;112(5):1114-21 [18219661.001]
  • [Cites] J Clin Oncol. 2008 Jul 10;26(20):3351-7 [18612151.001]
  • [Cites] Breast Cancer Res Treat. 2008 Sep;111(1):79-91 [17902048.001]
  • [Cites] J Thorac Oncol. 2008 Aug;3(8):815-8 [18670298.001]
  • [Cites] Clin Cancer Res. 2008 Oct 15;14(20):6364-70 [18927274.001]
  • [Cites] J Natl Cancer Inst. 2008 Dec 3;100(23):1672-94 [19033571.001]
  • [Cites] Cancer Res. 2009 Jan 1;69(1):161-70 [19117999.001]
  • [Cites] Ann Oncol. 2009 May;20(5):842-9 [19153117.001]
  • [Cites] Control Clin Trials. 1996 Aug;17(4):343-6 [8889347.001]
  • (PMID = 20351332.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA058187; United States / NCI NIH HHS / CA / P50 CA058187
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, IGF Type 1
  • [Other-IDs] NLM/ PMC2860435
  •  go-up   go-down


15. Liu M, Chen W, Li XR, Li JL, Wang JD, Zhang YJ, Zheng YQ, Wei LX: [Study on diagnostic accuracy of ultrasound-guided core needle breast biopsy]. Zhonghua Bing Li Xue Za Zhi; 2010 Nov;39(11):739-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study on diagnostic accuracy of ultrasound-guided core needle breast biopsy].
  • OBJECTIVE: to evaluate the diagnostic accuracy of ultrasound-guided core needle biopsy of breast tumors.
  • METHODS: six hundred and sixty-seven cases of core needle biopsy of breast encountered during the period from January, 2004 to June, 2007 were retrieved from the archival file and retrospectively reviewed.
  • RESULTS: three hundred and eighty-two patients had core needle biopsy diagnosis followed by local excision, breast conservation surgery or mastectomy.
  • The rate of underestimation for ductal carcinoma-in-situ was 6/11.
  • CONCLUSION: in order to improve the diagnostic accuracy of core needle biopsy of breast tumors, recognition of the limitation of the procedure, application of immunohistochemistry and awareness of potentially rare entities are important.
  • [MeSH-major] Biopsy, Needle / methods. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Mucinous / ultrasonography. Antigens, CD56 / metabolism. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Intraductal, Noninfiltrating / surgery. Carcinoma, Intraductal, Noninfiltrating / ultrasonography. False Negative Reactions. Female. Humans. Keratin-5 / metabolism. Mastectomy / methods. Membrane Proteins / metabolism. Retrospective Studies. Ultrasonography, Interventional / methods. Ultrasonography, Mammary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21215163.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / CKAP4 protein, human; 0 / Keratin-5; 0 / Membrane Proteins
  •  go-up   go-down


16. Lee JW, Soung YH, Seo SH, Kim SY, Park CH, Wang YP, Park K, Nam SW, Park WS, Kim SH, Lee JY, Yoo NJ, Lee SH: Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. Clin Cancer Res; 2006 Jan 1;12(1):57-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas.
  • PURPOSE: Recent reports revealed that the kinase domain of the ERBB2 gene is somatically mutated in lung adenocarcinoma, suggesting the mutated ERBB2 gene as an oncogene in human cancers.
  • EXPERIMENTAL DESIGN: Here, we did a mutational analysis of the ERBB2 kinase domain by PCR single-strand conformational polymorphism assay in gastric, colorectal, and breast carcinoma tissues.
  • RESULTS: We detected the ERBB2 kinase domain mutations in 9 of 180 gastric carcinomas (5.0%), in 3 of 104 colorectal carcinomas (2.9%), and in 4 of 94 breast carcinomas (4.3%).
  • CONCLUSION: This study showed that in addition to lung adenocarcinomas, ERBB2 kinase domain mutation occurs in other common human cancers such as gastric, breast, and colorectal cancers, and suggested that alterations of ERBB2-mediated signaling pathway by ERBB2 mutations alone or together with K-RAS mutations may contribute to the development of human cancers.
  • [MeSH-major] Breast Neoplasms / genetics. Colorectal Neoplasms / genetics. Genes, erbB-2 / genetics. Stomach Neoplasms / genetics
  • [MeSH-minor] Aged. DNA Mutational Analysis. Female. Genes, ras / genetics. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Mutation. Phosphatidylinositol 3-Kinases / genetics. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational. Proto-Oncogene Proteins B-raf / genetics. Receptor, Epidermal Growth Factor / genetics


17. Friedrich I, Eizenbach M, Sajman J, Ben-Bassat H, Levitzki A: A cellular screening assay to test the ability of PKR to induce cell death in mammalian cells. Mol Ther; 2005 Nov;12(5):969-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PKR can be selectively activated in glioblastoma cells by in situ generation of dsRNA following introduction of antisense RNA complementary to an RNA expressed specifically in these cells.
  • [MeSH-major] Adenocarcinoma / pathology. Cell Death / drug effects. Drug Screening Assays, Antitumor / methods. Glioblastoma / pathology. Ribonucleoproteins / therapeutic use. eIF-2 Kinase / pharmacology
  • [MeSH-minor] Animals. Breast Neoplasms / pathology. Cell Line, Tumor. Colonic Neoplasms / pathology. Hepatitis Delta Virus. Humans. Male. Mammals. Plasmids. Prostatic Neoplasms / pathology. RNA, Small Interfering

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16084774.001).
  • [ISSN] 1525-0016
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Small Interfering; 0 / Ribonucleoproteins; EC 2.7.11.1 / eIF-2 Kinase
  •  go-up   go-down


18. Istvanic S, Fischer AH, Banner BF, Eaton DM, Larkin AC, Khan A: Cell blocks of breast FNAs frequently allow diagnosis of invasion or histological classification of proliferative changes. Diagn Cytopathol; 2007 May;35(5):263-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell blocks of breast FNAs frequently allow diagnosis of invasion or histological classification of proliferative changes.
  • Two major limitations of breast fine needle aspiration (FNA) compared with core needle biopsies (CNB) are the inability to determine whether a cancer is invasive and to classify proliferative lesions.
  • We studied 40 consecutive "rapid cell blocks" from breast FNAs with surgical pathology follow-up to test whether cell blocks can overcome these limitations.
  • Cell blocks from 12 of 14 benign breast FNAs showed sufficient cells to assign a histologic diagnosis of no hyperplasia (1 case, confirmed on follow-up) and usual hyperplasia (11 cases; confirmed in eight of 11 on follow-up).
  • Specific histologic diagnoses included intraductal papilloma (2 cases), and in situ lobular neoplasia (2 cases).
  • Cell blocks complement smears and monolayers and appear to overcome major limitations of breast FNA.
  • [MeSH-major] Biopsy, Fine-Needle. Breast / pathology. Breast Neoplasms / pathology. Neoplasms, Ductal, Lobular, and Medullary / pathology. Paraffin Embedding / methods
  • [MeSH-minor] Adenocarcinoma / classification. Adenocarcinoma / pathology. Carcinoma in Situ / classification. Carcinoma in Situ / pathology. Carcinoma, Lobular / classification. Carcinoma, Lobular / pathology. Cell Proliferation. Female. Humans. Hyperplasia. Neoplasm Invasiveness. Papilloma, Intraductal / classification. Papilloma, Intraductal / pathology. Phyllodes Tumor / classification. Phyllodes Tumor / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17427225.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Jensen KC, Nielsen TO, Gilks CB, West RB: HER2 Intermediate Breast Cancers. Am J Surg Pathol; 2009 Nov;33(11):1739; author reply 1739-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HER2 Intermediate Breast Cancers.
  • [MeSH-major] Adenocarcinoma / chemistry. Breast Neoplasms / chemistry. Receptor, ErbB-2 / analysis
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / analysis. Combined Modality Therapy. Female. Gene Dosage. Guidelines as Topic. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Prognosis. Trastuzumab. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Am J Surg Pathol. 2009 May;33(5):759-67 [19252432.001]
  • (PMID = 19745698.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab
  •  go-up   go-down


20. Onuma K, Dabbs DJ, Bhargava R: Mammaglobin expression in the female genital tract: immunohistochemical analysis in benign and neoplastic endocervix and endometrium. Int J Gynecol Pathol; 2008 Jul;27(3):418-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mammaglobin (MGB), a secretory protein belonging to the uteroglobin/Clara cell protein family, is a sensitive marker for breast carcinoma, but is also reported to be expressed in the female genital tract and its neoplasms.
  • To investigate the potential use of MGB in gynecologic pathology practice, we tested MGB expression by immunohistochemistry on 47 endocervical adenocarcinomas (whole tissue sections of 13 invasive and 35 in situ) and 55 endometrial carcinomas (39 endometrioid and 16 nonendometrioid represented on a single tissue microarray).
  • Endocervical adenocarcinoma in situ (AIS) showed either weak (predominantly) or moderate (occasionally) expression in about 40% of the cases in comparison with strong positivity in benign endocervical glandular epithelium.
  • These results confirm that MGB is not specific for breast carcinoma, but is also variably expressed in nonneoplastic and neoplastic endocervical and endometrial tissues.
  • Frequent MGB expression in endometrioid endometrial adenocarcinoma is significantly different from nonendometrioid carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / biosynthesis. Carcinoma in Situ / metabolism. Neoplasm Proteins / biosynthesis. Uterine Neoplasms / metabolism. Uteroglobin / biosynthesis. Uterus / metabolism

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580321.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin
  •  go-up   go-down


21. Guest I, Ilic Z, Ma J, Grant D, Glinsky G, Sell S: Direct and indirect contribution of bone marrow-derived cells to cancer. Int J Cancer; 2010 May 15;126(10):2308-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One of the female FVB/N recipient mice also developed fibrosarcoma and 1, a diploid breast adenocarcinoma containing Y chromosomes.
  • These results indicate not only that the transgenic BM-derived stromal cells may indirectly contribute to development of tumors in recipient mice but also that sarcomas may arise by transformation of BM stem cells and that breast cancers arise by transdifferentiation of BM stem cells, presumably by mesenchymal-epithelial transition.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Mammary Gland Biol Neoplasia. 2004 Apr;9(2):183-93 [15300012.001]
  • [Cites] Mol Cancer Ther. 2004 Aug;3(8):941-53 [15299077.001]
  • [Cites] J Cell Biol. 2006 Mar 27;172(7):973-81 [16567498.001]
  • [Cites] Science. 2006 Mar 31;311(5769):1880-5 [16574858.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):392-401 [16572188.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4553-7 [16651403.001]
  • [Cites] Science. 2004 Nov 26;306(5701):1568-71 [15567866.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1755-60 [15753371.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):5991-5; discussion 5995 [16024595.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):5996-6000; discussion 6000-1 [16024596.001]
  • [Cites] Lancet Oncol. 2005 Dec;6(12):988-93 [16321767.001]
  • [Cites] Nature. 2006 Feb 23;439(7079):993-7 [16395311.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):8274-9 [16912208.001]
  • [Cites] Neoplasia. 2006 Sep;8(9):716-24 [16984729.001]
  • [Cites] Clin Cancer Res. 2006 Oct 1;12(19):5615-21 [17020963.001]
  • [Cites] Annu Rev Cell Dev Biol. 2006;22:287-309 [16824016.001]
  • [Cites] Stem Cell Rev. 2005;1(1):1-7 [17132868.001]
  • [Cites] Dev Biol. 2007 Mar 1;303(1):29-44 [17222404.001]
  • [Cites] Stem Cells. 2007 Aug;25(8):1881-7 [17478582.001]
  • [Cites] Cancer Cell. 2008 Jan;13(1):58-68 [18167340.001]
  • [Cites] Cancer Res. 2008 Feb 15;68(4):989-97 [18281472.001]
  • [Cites] Stem Cells. 2008 Jul;26(7):1768-77 [18467658.001]
  • [Cites] Semin Cancer Biol. 2008 Oct;18(5):311-21 [18455428.001]
  • [Cites] Breast Cancer Res Treat. 2009 Jan;113(2):211-3 [18264757.001]
  • [Cites] Trends Mol Med. 2009 Jan;15(1):5-13 [19091631.001]
  • [Cites] Hepatology. 2000 Jan;31(1):235-40 [10613752.001]
  • [Cites] Oncogene. 2000 Feb 21;19(8):992-1001 [10713682.001]
  • [Cites] Melanoma Res. 2000 Dec;10(6):507-14 [11198471.001]
  • [Cites] Nature. 2001 May 17;411(6835):375-9 [11357145.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8298-305 [11719463.001]
  • [Cites] Nat Med. 2002 Sep;8(9):1011-7 [12195435.001]
  • [Cites] Differentiation. 2002 Dec;70(9-10):498-505 [12492492.001]
  • [Cites] Differentiation. 2002 Dec;70(9-10):537-46 [12492495.001]
  • [Cites] Nature. 2003 Apr 24;422(6934):897-901 [12665832.001]
  • [Cites] J Pathol. 2003 Jul;200(4):429-47 [12845611.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):2113-26 [14578209.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3483-93 [12893756.001]
  • [Cites] Birth Defects Res C Embryo Today. 2003 Aug;69(3):209-18 [14671774.001]
  • [Cites] Lab Invest. 2004 Feb;84(2):245-52 [14688799.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):5973-81 [15342376.001]
  • [Cites] Cancer. 1974 Oct;34(4 Suppl):suppl:1488-503 [4608683.001]
  • [Cites] Mol Cell Biol. 1983 Apr;3(4):523-38 [6687920.001]
  • [Cites] Cancer Metastasis Rev. 1984;3(3):193-222 [6388823.001]
  • [Cites] Cancer Res. 1989 Nov 1;49(21):6085-90 [2477151.001]
  • [Cites] EMBO J. 1994 Dec 1;13(23):5570-80 [7988554.001]
  • [Cites] Toxicol Pathol. 1996 Nov-Dec;24(6):710-6 [8994298.001]
  • [Cites] N Engl J Med. 1997 Mar 27;336(13):897-904 [9070469.001]
  • [Cites] Bone Marrow Transplant. 2004 Dec;34(11):981-5 [15502854.001]
  • (PMID = 19816927.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 1-R01-CA112481; United States / NIA NIH HHS / AG / R01 AG023510; United States / NCI NIH HHS / CA / R01 CA112481; United States / NCI NIH HHS / CA / R01 CA112481-05; United States / NIA NIH HHS / AG / 1-R01-AG023510
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS163514; NLM/ PMC3051419
  •  go-up   go-down


22. Datta D, Flaxenburg JA, Laxmanan S, Geehan C, Grimm M, Waaga-Gasser AM, Briscoe DM, Pal S: Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer. Cancer Res; 2006 Oct 1;66(19):9509-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer.
  • Human breast cancer cells express the chemokine CXCL10 (IP-10) and also its receptor CXCR3.
  • In this study, we have investigated the role of Ras activation in the regulation of CXCL10 and its receptor splice variant CXCR3-B in two human breast cancer cell lines MDA-MB-435 and MCF-7.
  • Selective inhibition of CXCR3-B using siRNA resulted in an increase in CXCL10-mediated breast cancer cell proliferation through G(i) proteins and likely involving CXCR3-A.
  • Finally, we observed intense expression of CXCL10 and CXCR3 in association with human breast cancer in situ, indicating that these observations may be of pathophysiologic significance.
  • Together, these results suggest that activation of Ras plays a critical role in modulating the expression of both CXCL10 and CXCR3-B, which may have important consequences in the development of breast tumors through cancer cell proliferation.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17018607.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL74436; United States / PHS HHS / / DBU16011; United States / NIDDK NIH HHS / DK / DK64182; United States / NHLBI NIH HHS / HL / R01 HL074436; United States / NIDDK NIH HHS / DK / T32 DK007726
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CXCL10 protein, human; 0 / CXCR3 protein, human; 0 / Chemokine CXCL10; 0 / Chemokines, CXC; 0 / Neoplasm Proteins; 0 / Protein Isoforms; 0 / RNA, Small Interfering; 0 / Receptors, CXCR3; 0 / Receptors, Chemokine; 0 / Recombinant Fusion Proteins; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-raf; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras); W36ZG6FT64 / Sirolimus
  •  go-up   go-down


23. Souazé F, Dupouy S, Viardot-Foucault V, Bruyneel E, Attoub S, Gespach C, Gompel A, Forgez P: Expression of neurotensin and NT1 receptor in human breast cancer: a potential role in tumor progression. Cancer Res; 2006 Jun 15;66(12):6243-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of neurotensin and NT1 receptor in human breast cancer: a potential role in tumor progression.
  • In a series of 51 patients with invasive ductal breast cancers, 34% of all tumors were positive for neurotensin and 91% positive for NT1 receptor.
  • We found a coexpression of neurotensin and NT1 receptor in a large proportion (30%) of ductal breast tumors, suggesting a contribution of the neurotensinergic signaling cascade within breast cancer progression.
  • Functionally expressed NT1 receptor, in the highly malignant MDA-MB-231 human breast cancer cell line, coordinated a series of transforming functions, including cellular migration, invasion, induction of the matrix metalloproteinase (MMP)-9 transcripts, and MMP-9 gelatinase activity.
  • Our findings support the contribution of neurotensin in human breast cancer progression and point out the utility to develop therapeutic molecules targeting neurotensin or NT1 receptor signaling cascade.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Neurotensin / biosynthesis. Receptors, Neurotensin / biosynthesis
  • [MeSH-minor] Animals. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Cell Growth Processes / physiology. Cell Line, Tumor. Cell Movement / physiology. Disease Progression. Enzyme Activation. Female. Humans. Immunohistochemistry. Matrix Metalloproteinase 9 / metabolism. Mice. Middle Aged. Neoplasm Invasiveness. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16778199.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Neurotensin; 0 / neurotensin type 1 receptor; 39379-15-2 / Neurotensin; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


24. Garedew A, Kämmerer U, Singer D: Respiratory response of malignant and placental cells to changes in oxygen concentration. Respir Physiol Neurobiol; 2009 Feb 28;165(2-3):154-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant cells and foetal tissues are exposed to low oxygen partial pressure (pO2) in situ due to the limited supply of oxygenated blood.
  • [MeSH-major] Breast Neoplasms / metabolism. Leukocytes / metabolism. Oxygen / pharmacology. Oxygen Consumption / physiology. Placenta / cytology
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Cell Hypoxia / physiology. Cell Line, Tumor. Cell Respiration / physiology. Endothelial Cells / cytology. Endothelial Cells / metabolism. Female. Fetus / cytology. Humans. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Umbilical Veins / cytology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19041734.001).
  • [ISSN] 1569-9048
  • [Journal-full-title] Respiratory physiology & neurobiology
  • [ISO-abbreviation] Respir Physiol Neurobiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] S88TT14065 / Oxygen
  •  go-up   go-down


25. Kikuchi Y, Kashima TG, Nishiyama T, Shimazu K, Morishita Y, Shimazaki M, Kii I, Horie H, Nagai H, Kudo A, Fukayama M: Periostin is expressed in pericryptal fibroblasts and cancer-associated fibroblasts in the colon. J Histochem Cytochem; 2008 Aug;56(8):753-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pericryptal pattern of periostin deposition was decreased in adenoma and adenocarcinoma, preceding the decrease of the number of pericryptal fibroblasts.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Cell Adhesion Molecules / biosynthesis. Colon / metabolism. Colonic Neoplasms / metabolism. Fibroblasts / metabolism
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Proliferation. Cells, Cultured. Coculture Techniques. Collagen Type I. Gels. Humans. Immunohistochemistry. In Situ Hybridization. Intestinal Mucosa / metabolism. Intestinal Mucosa / pathology. Lung / cytology. Mice. Mice, Inbred ICR. Microscopy, Immunoelectron. Reverse Transcriptase Polymerase Chain Reaction

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2001 Aug 15;92(4):843-8 [11550156.001]
  • [Cites] Mech Dev. 2001 May;103(1-2):183-8 [11335131.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):98-104 [11689954.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5358-64 [12235007.001]
  • [Cites] Breast Cancer Res Treat. 2003 Feb;77(3):245-52 [12602924.001]
  • [Cites] Gastroenterology. 2004 Jan;126(1):111-21 [14699493.001]
  • [Cites] Dev Dyn. 2004 Apr;229(4):857-68 [15042709.001]
  • [Cites] Mol Cell Biol. 2004 May;24(9):3992-4003 [15082792.001]
  • [Cites] Cancer Cell. 2004 Apr;5(4):329-39 [15093540.001]
  • [Cites] Hum Pathol. 1993 May;24(5):525-33 [8491492.001]
  • [Cites] Biochem J. 1993 Aug 15;294 ( Pt 1):271-8 [8363580.001]
  • [Cites] Annu Rev Cell Biol. 1993;9:511-40 [8280470.001]
  • [Cites] Cancer Res. 1997 May 1;57(9):1644-9 [9135000.001]
  • [Cites] J Physiol. 1999 Jan 1;514 ( Pt 1):211-27 [9831728.001]
  • [Cites] J Gastroenterol. 1999 Apr;34(2):215-20 [10213121.001]
  • [Cites] J Bone Miner Res. 1999 Jul;14(7):1239-49 [10404027.001]
  • [Cites] Pathol Int. 1999 May;49(5):426-34 [10417686.001]
  • [Cites] Am J Physiol. 1999 Aug;277(2 Pt 1):C183-201 [10444394.001]
  • [Cites] Anat Rec A Discov Mol Cell Evol Biol. 2004 Dec;281(2):1264-75 [15386274.001]
  • [Cites] Carcinogenesis. 2005 May;26(5):908-15 [15731169.001]
  • [Cites] Cell. 2005 May 6;121(3):335-48 [15882617.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Apr 14;342(3):766-72 [16497272.001]
  • [Cites] J Allergy Clin Immunol. 2006 Jul;118(1):98-104 [16815144.001]
  • [Cites] J Biol Chem. 2006 Jul 14;281(28):19700-8 [16702213.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):6928-35 [16849536.001]
  • [Cites] Breast Cancer Res. 2006;8(5):R56 [17014703.001]
  • [Cites] Oncogene. 2007 Mar 29;26(14):2082-94 [17043657.001]
  • [Cites] Gastroenterology. 2007 Apr;132(4):1447-64 [17408641.001]
  • [Cites] J Cell Biochem. 2007 Jun 1;101(3):695-711 [17226767.001]
  • [Cites] J Exp Med. 2008 Feb 18;205(2):295-303 [18208976.001]
  • [Cites] Mod Pathol. 2008 Aug;21(8):1044-53 [18487994.001]
  • [Cites] J Bone Miner Metab. 2000;18(3):132-9 [10783846.001]
  • [Cites] J Lab Clin Med. 2000 Sep;136(3):201-8 [10985498.001]
  • [Cites] J Gastroenterol Hepatol. 2001 Sep;16(9):991-1000 [11595063.001]
  • (PMID = 18443362.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / Collagen Type I; 0 / Gels; 0 / POSTN protein, human; 0 / Postn protein, mouse
  • [Other-IDs] NLM/ PMC2443605
  •  go-up   go-down


26. Colleau M, Magalon G, Bonnier P: [Breast carcinoma diagnosed from surgical specimens. Retrospective study on three years]. Ann Chir Plast Esthet; 2005 Apr;50(2):127-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Breast carcinoma diagnosed from surgical specimens. Retrospective study on three years].
  • In the wake of three consecutive cases of microscopical examination of resection specimens following breast reduction revealing an adenocarcinoma, we wanted to point out the interest of a complete preoperative senological examination including mammography and postoperative anatomopathological examination.
  • We found seven patients (0.83%) with malignant breast cancer diagnosed on anatomopathological examination, which is comparable to the incidence found in literature.
  • Of these seven cases there were four ductal adenocarcinomas (0.47%), all of them in situ (DCIS), and three lobular adenocarcinomas (0.36%) of which one invasive (ILA), one in situ (LCIS) and one mixed.
  • In our opinion this shows that breast reduction can help in tracking down breast cancer and underlines the need for systematic and meticulous microscopic examination of resection specimens after breast reduction.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / surgery. Mastectomy

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15820598.001).
  • [ISSN] 0294-1260
  • [Journal-full-title] Annales de chirurgie plastique et esthétique
  • [ISO-abbreviation] Ann Chir Plast Esthet
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


27. Stuckey A, Dizon D, Scalia Wilbur J, Kent J, Tejada-Berges T, Gass J, Legare R: Clinical characteristics and choices regarding risk-reducing surgery in BRCA mutation carriers. Gynecol Obstet Invest; 2010;69(4):270-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: BRCA mutation carriers have a high lifetime risk of developing breast and ovarian malignancies.
  • They were more likely to be a BRCA2 mutation carrier, parous, married, employed, and had a prior history of breast cancer.
  • Pathology was typically benign; however, 15% showed ductal carcinoma in situ of the breast, 8% reported infiltrating ductal carcinoma of the breast, 3% was adenocarcinoma of the fallopian tube, and 3% was adenocarcinoma of the ovary.
  • [MeSH-major] BRCA1 Protein / genetics. BRCA2 Protein / genetics. Breast Neoplasms / prevention & control. Mutation. Ovarian Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 S. Karger AG, Basel.
  • (PMID = 20090358.001).
  • [ISSN] 1423-002X
  • [Journal-full-title] Gynecologic and obstetric investigation
  • [ISO-abbreviation] Gynecol. Obstet. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / BLID protein, human; 0 / BRCA1 Protein; 0 / BRCA1 protein, human; 0 / BRCA2 Protein; 0 / BRCA2 protein, human
  •  go-up   go-down


28. Sung JS, Park KH, Kim YH: Genomic alterations of chromosome region 11p as predictive marker by array comparative genomic hybridization in lung adenocarcinoma patients. Cancer Genet Cytogenet; 2010 Apr 1;198(1):27-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic alterations of chromosome region 11p as predictive marker by array comparative genomic hybridization in lung adenocarcinoma patients.
  • To further validate the gain of chromosome 11p region that was identified by array CGH, fluorescence in situ hybridization (FISH) was performed.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosomes, Human, Pair 11. Comparative Genomic Hybridization / methods. DNA Copy Number Variations. Lung Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chromosome Aberrations. Female. Genetic Markers. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Recurrence

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20303011.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Genetic Markers
  •  go-up   go-down


29. McLaren BK, Gobbi H, Schuyler PA, Olson SJ, Parl FF, Dupont WD, Page DL: Immunohistochemical expression of estrogen receptor in enlarged lobular units with columnar alteration in benign breast biopsies: a nested case-control study. Am J Surg Pathol; 2005 Jan;29(1):105-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of estrogen receptor in enlarged lobular units with columnar alteration in benign breast biopsies: a nested case-control study.
  • The prognostic and therapeutic implications of estrogen receptor (ER) status in breast cancer are well known.
  • Whether ER status plays a role in benign breast lesions and the progression to malignancy has not been proven.
  • Enlarged lobular units with columnar alteration (ELUCA), also known as unfolded lobular units, have been associated with mild elevations in subsequent breast cancer risk.
  • We examined the association of ERalpha expression in ELUCA with invasive breast cancer risk.
  • A nested case-control study was performed of women with ELUCA who had undergone benign breast surgery.
  • Eighty-two women who developed invasive breast cancer on follow-up were matched by age and year of biopsy with 166 women who did not develop invasive breast cancer.
  • Relative risks of breast cancer were estimated by odds ratios derived from conditional logistic regression analyses.
  • The relative risk of invasive breast cancer in women with ERalpha-negative ELUCA was 1.85 times that of women with ERalpha-positive lesions (95% confidence interval, 1.0-3.4, P=0.04).
  • These findings have implications for risk assessment in benign breast biopsies and are of particular interest given the controversy currently surrounding hormone replacement therapy.
  • [MeSH-major] Adenocarcinoma / metabolism. Breast / metabolism. Breast Neoplasms / metabolism. Carcinoma in Situ / metabolism. Precancerous Conditions / metabolism. Receptors, Estrogen / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15613861.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen
  •  go-up   go-down


30. Sitterding SM, Wiseman WR, Schiller CL, Luan C, Chen F, Moyano JV, Watkin WG, Wiley EL, Cryns VL, Diaz LK: AlphaB-crystallin: a novel marker of invasive basal-like and metaplastic breast carcinomas. Ann Diagn Pathol; 2008 Feb;12(1):33-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AlphaB-crystallin: a novel marker of invasive basal-like and metaplastic breast carcinomas.
  • Basal-like tumors are a newly recognized estrogen receptor (ER) negative and HER2 negative breast cancer subtype that express basal epithelial genes and are associated with poor survival.
  • The current study examined the rates and patterns of alphaB-crystallin expression in whole tissue sections of human breast, including normal tissue, proliferative lesions, in situ and invasive carcinomas (ER positive, HER2 positive, basal-like, and metaplastic cancers).
  • In normal breast tissue, proliferative lesions and in situ carcinomas, alphaB-crystallin expression was restricted to the myoepithelial cell compartment of ductal and lobular units.
  • Conversely, no staining for alphaB-crystallin was observed in nonbasal-like (ie, ER positive or HER2 positive) breast carcinomas.
  • Taken together, our results indicate that alphaB-crystallin is a sensitive (81%) and specific (100%) marker for basal-like breast carcinomas.
  • Moreover, the high rates of expression of alphaB-crystallin in metaplastic breast carcinomas (86%) suggest that these tumors may represent a histologically distinctive subset of basal-like breast tumors with a similar underlying molecular etiology.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Breast Neoplasms / metabolism. Neoplasm Proteins / metabolism. alpha-Crystallin B Chain / metabolism
  • [MeSH-minor] Breast Cyst / metabolism. Breast Cyst / pathology. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Cell Proliferation. Female. Fibrocystic Breast Disease / metabolism. Fibrocystic Breast Disease / pathology. Fluorescent Antibody Technique, Indirect. Humans. Immunoenzyme Techniques. Metaplasia. Neoplasm Invasiveness. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18164413.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50CA89018; United States / NCI NIH HHS / CA / R01CA097198
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / alpha-Crystallin B Chain
  •  go-up   go-down


31. Sato T, Muto I, Fushiki M, Hasegawa M, Hasegawa M, Sakai T, Sekiya M: Metastatic breast cancer from gastric and ovarian cancer, mimicking inflammatory breast cancer: report of two cases. Breast Cancer; 2008;15(4):315-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic breast cancer from gastric and ovarian cancer, mimicking inflammatory breast cancer: report of two cases.
  • Breast metastases from extra-mammary malignancies, especially those mimicking primary inflammatory breast carcinoma, are extremely rare.
  • We report here two cases of inflammatory breast metastases from gastric or ovarian cancer.
  • Both patients, who had prior advanced malignant disease, presented with unilateral breast redness and swelling with peau d'orange sign, resembling primary inflammatory breast cancer or acute mastitis.
  • Breast biopsy revealed poorly differentiated adenocarcinoma with signet-ring cells or clear cell carcinoma in the lymphatic vessels and the parenchyma without an in situ lesion, similar to primary lesions of the stomach or ovary, respectively.
  • Immunohistochemical staining for estrogen receptor, progesterone receptor, and gross cystic disease fluid protein 15 was of value for correct diagnosis.
  • Since breast metastasis is a sign of poor prognosis of the primary malignant disease, the possibility of breast metastasis should be considered in appropriate patients to preclude unnecessary major surgery.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / secondary. Ovarian Neoplasms / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Clear Cell / therapy. Aged. Diagnosis, Differential. Female. Humans. Middle Aged. Tomography, X-Ray Computed


32. Popnikolov NK, Cavone SM, Schultz PM, Garcia FU: Diagnostic utility of p75 neurotrophin receptor (p75NTR) as a marker of breast myoepithelial cells. Mod Pathol; 2005 Dec;18(12):1535-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic utility of p75 neurotrophin receptor (p75NTR) as a marker of breast myoepithelial cells.
  • We evaluated the low affinity neurotrophin receptor (p75NTR) as a marker of breast myoepithelial cells.
  • Immunohistochemical staining for p75NTR was performed on paraffin sections of 122 malignant breast lesions, 28 benign lesions and the adjacent normal breast tissue.
  • The staining pattern was compared to those of myosin heavy chain and p63. p75NTR immunostain was consistently positive and compatible with p63 and myosin immunoreactivity in the myoepithelial cells of the normal mammary gland, benign breast lesions (six usual ductal hyperplasias, six specimens with sclerosing adenosis, eight intraductal papillomas, six fibroadenomas), and carcinoma in situ (18 ductal carcinomas in situ, two noninvasive papillary carcinomas, two lobular carcinomas in situ).
  • No p75NTR expression was found in the malignant cells in all in situ carcinomas, invasive lobular carcinomas (n = 11), tubular carcinomas (n = 10), invasive papillary carcinomas (n = 6), mucinous carcinomas (n = 4), and medullary carcinomas (n = 2).
  • Our study shows that p75NTR is a useful marker for breast myoepithelial cells and can be used to rule out invasive disease as well as to evaluate difficult for diagnosis sclerosing lesions.
  • Our data suggest a role of neurotrophins in the development of fibroepithelial breast tumors and some of the breast carcinomas.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / metabolism. Breast / pathology. Breast Neoplasms / pathology. Epithelial Cells / pathology. Muscle, Smooth / pathology. Receptor, Nerve Growth Factor / metabolism
  • [MeSH-minor] Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / pathology. Female. Fibroadenoma / metabolism. Fibroadenoma / pathology. Fibrocystic Breast Disease / metabolism. Fibrocystic Breast Disease / pathology. Humans. Hyperplasia / metabolism. Hyperplasia / pathology. Immunoenzyme Techniques. Myosin Heavy Chains / metabolism. Papilloma, Intraductal / metabolism. Papilloma, Intraductal / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258511.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptor, Nerve Growth Factor; EC 3.6.4.1 / Myosin Heavy Chains
  •  go-up   go-down


33. Kunju LP, Ding Y, Kleer CG: Tubular carcinoma and grade 1 (well-differentiated) invasive ductal carcinoma: comparison of flat epithelial atypia and other intra-epithelial lesions. Pathol Int; 2008 Oct;58(10):620-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of 14 TC, eight (57%) had associated FEA, seven (50%) had micropapillary atypical ductal hyperplasia (ADH), three (21%) had low nuclear grade ductal carcinoma in situ (DCIS), and four (29%) had lobular neoplasia.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Carcinoma, Intraductal, Noninfiltrating / metabolism. Cell Nucleus / metabolism. Cell Nucleus / pathology. Epithelial Cells / pathology. Female. Humans. In Situ Hybridization, Fluorescence. Lymph Nodes / pathology. Lymphatic Metastasis. Middle Aged. Prognosis. Receptor, ErbB-2 / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18801081.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA107469; United States / NCI NIH HHS / CA / CA090876; United States / NCI NIH HHS / CA / CA107469
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


34. Elloul S, Elstrand MB, Nesland JM, Tropé CG, Kvalheim G, Goldberg I, Reich R, Davidson B: Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer; 2005 Apr 15;103(8):1631-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma.
  • For the current study, the authors analyzed the relation between the expression of Snail, Slug, and Sip1; the expression of MMP-2 and E-cadherin; and clinical parameters in patients with metastatic ovarian and breast carcinoma.
  • METHODS: One hundred one fresh-frozen, malignant effusions from patients who were diagnosed with gynecologic carcinomas (78 ovarian carcinomas and 23 breast carcinomas) were studied for mRNA expression of Snail, Slug, Sip1, MMP-2, and E-cadherin using reverse transcriptase-polymerase chain reaction analysis.
  • Snail mRNA and E-cadherin protein expression levels also were studied in ovarian carcinoma effusions using in situ hybridization and immunocytochemistry.
  • RESULTS: E-cadherin mRNA expression was lower in breast carcinoma (P = 0.001), whereas Snail expression was higher (P = 0.003).
  • The Snail/E-cadherin ratio (P < 0.001) and the Sip1/E-cadherin ratio (P = 0.002) were higher in breast carcinomas.
  • The Sip1/E-cadherin ratio was higher in primary ovarian carcinomas at the time of diagnosis compared with postchemotherapy ovarian carcinoma effusions (P = 0.003), higher in Stage IV tumors compared with Stage III tumors (P = 0.049), and higher in pleural effusions compared with peritoneal effusions (P = 0.044).
  • High Snail mRNA expression predicted shorter effusion-free survival (P = 0.008), disease-free survival (P = 0.03), and overall survival (P = 0.008) in patients with breast carcinoma.
  • CONCLUSIONS: Transcription factors that regulate E-cadherin were expressed differentially in metastatic ovarian and breast carcinoma.
  • Snail may predict a poor outcome in patients who have breast carcinoma metastatic to effusions.
  • This finding was in agreement with the stronger suppression of E-cadherin by Snail and Sip1 in breast carcinoma effusions, a clinical condition associated with extremely poor survival.
  • [MeSH-major] Breast Neoplasms / genetics. DNA-Binding Proteins / genetics. Drosophila Proteins / genetics. Gene Expression Regulation, Neoplastic. Homeodomain Proteins / genetics. Ovarian Neoplasms / genetics. Repressor Proteins / genetics. Transcription Factors / genetics
  • [MeSH-minor] Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / secondary. Adult. Aged. Cadherins / genetics. Cadherins / metabolism. Carcinoma, Ductal / genetics. Carcinoma, Ductal / metabolism. Carcinoma, Ductal / secondary. Carcinoma, Lobular / genetics. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / secondary. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / secondary. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization. Matrix Metalloproteinase 2 / genetics. Matrix Metalloproteinase 2 / metabolism. Middle Aged. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 American Cancer Society.
  • (PMID = 15742334.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins; 0 / DNA-Binding Proteins; 0 / Drosophila Proteins; 0 / Homeodomain Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Repressor Proteins; 0 / Transcription Factors; 0 / ZEB2 protein, human; 0 / snail family transcription factors; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


35. Barros-Silva JD, Leitão D, Afonso L, Vieira J, Dinis-Ribeiro M, Fragoso M, Bento MJ, Santos L, Ferreira P, Rêgo S, Brandão C, Carneiro F, Lopes C, Schmitt F, Teixeira MR: Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer; 2009 Feb 10;100(3):487-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we evaluated the ERBB2 status in 463 gastric carcinomas using immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH), and compared the findings with histopathological characteristics and with disease-specific survival.
  • [MeSH-major] Adenocarcinoma / genetics. Genes, erbB-2. Stomach Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cross-Sectional Studies. Gene Amplification. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Middle Aged. Survival Analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genomics. 1989 Apr;4(3):362-6 [2565881.001]
  • [Cites] Oncogene. 1989 Jan;4(1):81-8 [2563577.001]
  • [Cites] Hum Pathol. 1990 Mar;21(3):325-32 [2312109.001]
  • [Cites] Mod Pathol. 1992 Jul;5(4):384-90 [1353880.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):3942-6 [8099528.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1441-7 [8336183.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3845-52 [8033105.001]
  • [Cites] Int Surg. 1994 Jan-Mar;79(1):27-32 [8063551.001]
  • [Cites] Oncogene. 1997 Jul 31;15(5):537-47 [9247307.001]
  • [Cites] Lab Invest. 1998 Mar;78(3):345-51 [9520947.001]
  • [Cites] J Gastrointest Surg. 1998 Mar-Apr;2(2):126-31 [9834407.001]
  • [Cites] Cancer. 1999 May 1;85(9):1894-902 [10223227.001]
  • [Cites] Oncogene. 1999 Apr 1;18(13):2241-51 [10327070.001]
  • [Cites] Virchows Arch. 2004 Sep;445(3):255-62 [15517369.001]
  • [Cites] Ann Oncol. 2005 Feb;16(2):273-8 [15668283.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Clin Breast Cancer. 2005 Aug;6(3):240-6 [16137435.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1659-72 [16236737.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1673-84 [16236738.001]
  • [Cites] World J Surg. 2005 Nov;29(11):1422-7; discussion 1428 [16222448.001]
  • [Cites] Gastric Cancer. 2005;8(4):249-52 [16328600.001]
  • [Cites] Dig Dis Sci. 2006 Aug;51(8):1371-9 [16868827.001]
  • [Cites] Mol Syst Biol. 2006;2:54 [17016520.001]
  • [Cites] Cell Oncol. 2006;28(5-6):283-94 [17167181.001]
  • [Cites] Hum Pathol. 2007 Sep;38(9):1386-93 [17555797.001]
  • [Cites] Eur J Cancer. 1999 Jul;35(7):1059-64 [10533448.001]
  • [Cites] Eur J Cancer. 2000 Feb;36(3):390-6 [10708942.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):16-7 [10973239.001]
  • [Cites] Ann Oncol. 2000 Jul;11(7):837-43 [10997811.001]
  • [Cites] J Clin Oncol. 2000 Nov 1;18(21):3651-64 [11054438.001]
  • [Cites] N Engl J Med. 2001 Mar 15;344(11):783-92 [11248153.001]
  • [Cites] Mod Pathol. 2001 Jun;14(6):556-62 [11406656.001]
  • [Cites] Acta Oncol. 2001;40(2-3):309-26 [11441938.001]
  • [Cites] Ann Oncol. 2001 Aug;12(8):1178-80 [11583204.001]
  • [Cites] Am J Clin Oncol. 2002 Feb;25(1):84-9 [11823704.001]
  • [Cites] Int J Cancer. 2002 Apr 20;98(6):833-7 [11948459.001]
  • [Cites] World J Gastroenterol. 2002 Dec;8(6):1023-8 [12439918.001]
  • [Cites] J Pathol. 2003 Apr;199(4):418-23 [12635131.001]
  • [Cites] Eur J Surg. 2002;168(11):597-608 [12699095.001]
  • [Cites] Int J Cancer. 2004 Apr 20;109(4):548-53 [14991576.001]
  • [Cites] Cancer. 1977 Jun;39(6):2475-85 [872047.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Dec;81(23):7308-12 [6095284.001]
  • [Cites] Science. 1986 Jun 27;232(4758):1644-6 [3012781.001]
  • [Cites] Science. 1989 May 12;244(4905):707-12 [2470152.001]
  • (PMID = 19156142.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2658544
  •  go-up   go-down


36. Rossi E, Villanacci V, Bassotti G, Donato F, Festa A, Cengia G, Grisanti S, Cestari R: TOPOIIalpha and HER-2/neu overexpression/amplification in Barrett's oesophagus, dysplasia and adenocarcinoma. Histopathology; 2010 Jul;57(1):81-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TOPOIIalpha and HER-2/neu overexpression/amplification in Barrett's oesophagus, dysplasia and adenocarcinoma.
  • AIMS: Topoisomerase IIalpha (TOPOIIalpha) and HER-2/neu are chromosome 17q genes coamplified in various cancers; no data exist for Barrett's oesophagus (BO) and BO adenocarcinoma (ADC).
  • METHODS AND RESULTS: Forty-four patients [18 BO, 13 BO with dysplasia (five low-grade dysplasia, eight high-grade dysplasia) and 13 ADC in BO] were evaluated by immunohistochemistry and fluorescence in situ hybridization (FISH).
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Antigens, Neoplasm / genetics. Barrett Esophagus / genetics. Barrett Esophagus / pathology. DNA Topoisomerases, Type II / genetics. DNA-Binding Proteins / genetics. Esophageal Neoplasms / genetics. Esophageal Neoplasms / pathology. Genes, erbB-2
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Aneuploidy. Chromosomes, Human, Pair 17 / genetics. Diagnosis, Differential. Female. Gene Amplification. Gene Expression. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Receptor, ErbB-2 / metabolism. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neoplasma. 2006;53(5):393-401 [17013533.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2893-8 [17363613.001]
  • [Cites] Dig Liver Dis. 2007 Apr;39(4):305-11 [17307036.001]
  • [Cites] Mod Pathol. 2007 May;20(5):584-91 [17396141.001]
  • [Cites] J Clin Pathol. 2007 Jul;60(7):768-72 [16882699.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5115-23 [17785566.001]
  • [Cites] Hum Pathol. 2008 Mar;39(3):403-9 [18261624.001]
  • [Cites] Clin Cancer Res. 2008 Oct 15;14(20):6440-8 [18927283.001]
  • [Cites] Minerva Gastroenterol Dietol. 2008 Dec;54(4):347-53 [19047975.001]
  • [Cites] J Cell Mol Med. 2009 Sep;13(9B):3826-33 [19292734.001]
  • [Cites] Hum Pathol. 2000 Jan;31(1):35-9 [10665910.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):839-47 [10702400.001]
  • [Cites] Anal Cell Pathol. 2000;20(1):25-32 [11007435.001]
  • [Cites] J Natl Cancer Inst. 2000 Dec 20;92(24):1991-8 [11121461.001]
  • [Cites] J Clin Pathol. 2000 Dec;53(12):890-2 [11265171.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1061-7 [11948114.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1107-16 [12006526.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3857-62 [12473600.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):676-84 [12951586.001]
  • [Cites] Clin Breast Cancer. 2003 Aug;4(3):179-86 [14499010.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Apr;39(4):288-97 [14978790.001]
  • [Cites] J Clin Pathol. 2004 Mar;57(3):233-7 [14990588.001]
  • [Cites] Neoplasma. 2004;51(3):193-7 [15254672.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):11-6 [15261138.001]
  • [Cites] Genes Chromosomes Cancer. 1990 May;2(1):63-70 [1980607.001]
  • [Cites] Anticancer Drugs. 1995 Apr;6(2):195-211 [7795268.001]
  • [Cites] Am J Pathol. 1997 Sep;151(3):761-8 [9284825.001]
  • [Cites] Hum Pathol. 1997 Oct;28(10):1180-8 [9343325.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 16;90(18):1346-60 [9747866.001]
  • [Cites] Stem Cells. 1998;16(6):413-28 [9831867.001]
  • [Cites] Am J Clin Pathol. 2005 Jan;123(1):28-35 [15762277.001]
  • [Cites] Hum Pathol. 2005 Apr;36(4):348-56 [15891995.001]
  • [Cites] Ann Surg Oncol. 2006 Jan;13(1):12-30 [16378161.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):69-83 [16514135.001]
  • [Cites] Hum Pathol. 2006 Oct;37(10):1333-43 [16949920.001]
  • (PMID = 20557373.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  • [Other-IDs] NLM/ PMC2916224
  •  go-up   go-down


37. Gallego R, Pintos E, García-Caballero T, Raghay K, Boulanger L, Beiras A, Gaudreau P, Morel G: Cellular distribution of growth hormone-releasing hormone receptor in human reproductive system and breast and prostate cancers. Histol Histopathol; 2005 07;20(3):697-706
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cellular distribution of growth hormone-releasing hormone receptor in human reproductive system and breast and prostate cancers.
  • Moreover, GHRH-R was demonstrated in prostate and breast carcinomas, opening a variety of possibilities for the use of GHRH antagonists in the treatment of prostatic and mammary tumors.
  • [MeSH-major] Breast Neoplasms / metabolism. Ovary / metabolism. Prostatic Neoplasms / metabolism. Receptors, Neuropeptide / metabolism. Receptors, Pituitary Hormone-Regulating Hormone / metabolism. Testis / metabolism
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Female. Humans. Immunohistochemistry. In Situ Hybridization. Male. Mammary Glands, Human / metabolism. Placenta / metabolism. Pregnancy. RNA, Messenger / genetics. RNA, Messenger / metabolism. Uterus / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15944917.001).
  • [ISSN] 0213-3911
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Neuropeptide; 0 / Receptors, Pituitary Hormone-Regulating Hormone; 0 / somatotropin releasing hormone receptor
  •  go-up   go-down


38. Horn LC, Meinel A, Handzel R, Einenkel J: Histopathology of endometrial hyperplasia and endometrial carcinoma: an update. Ann Diagn Pathol; 2007 Aug;11(4):297-311
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diagnostic criteria of endometrial hyperplasia, endometrial in situ carcinoma, and of the different histologic types of EC, according to the most recent World Health Organization classification, are given in detail.
  • Endometrial pathologies in patients with breast cancer, receiving tamoxifen, and women affected by hereditary nonpolyposis colorectal cancer syndrome are described, including their pathogenetic aspects.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma in Situ / pathology. Endometrial Hyperplasia / pathology. Endometrial Neoplasms / pathology. Pathology, Surgical / methods. Precancerous Conditions / pathology
  • [MeSH-minor] Adenocarcinoma, Clear Cell / classification. Adenocarcinoma, Clear Cell / pathology. Antineoplastic Agents, Hormonal / adverse effects. Carcinoma, Endometrioid / classification. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / classification. Cystadenocarcinoma, Serous / pathology. Endometrium / drug effects. Endometrium / pathology. Female. Humans. Specimen Handling / methods. Tamoxifen / adverse effects

  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Diagn Pathol. 2008 Jun;12(3):231-2; author reply 232-3 [18486902.001]
  • (PMID = 17630117.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  • [Number-of-references] 92
  •  go-up   go-down


39. Fujiwara A, Shibata E, Terashima H, Shishido A, Nishiki J, Yoshida K, Miyauchi K, Madachi A, Matsuura N: Evaluation of matrix metalloproteinase-2 (MMP-2) activity with film in situ zymography for improved cytological diagnosis of breast tumors. Breast Cancer; 2006;13(3):272-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of matrix metalloproteinase-2 (MMP-2) activity with film in situ zymography for improved cytological diagnosis of breast tumors.
  • BACKGROUND: Fine-needle aspiration (FNA) biopsy of breast tumors is a reliable diagnostic method for identifying breast carcinoma.
  • To improve the cytological diagnosis of breast tumors, we investigated the expression of active matrix metalloproteinase-2 (MMP-2), as detected by film in situ zymography (FIZ).
  • METHODS: We evaluated 34 fresh breast tumors, 25 paraffin-embedded breast tissue specimens, and a human cancer cell line (HT1080).
  • Frozen sections and aspiration cytology samples of breast cancer were incubated on gelatin-coated films for the detection of active MMP-2.
  • RESULTS: Immunohistochemistry showed that MMP-2 was expressed in cancer cells and stromal cells, but not in most benign breast lesions.
  • Gelatinolytic activity was also detected by FIZ analysis of aspiration cytology samples and frozen sections from the breast cancers, and there was a significant correlation between this gelatinolytic activity and the detection of MMP-2 expression by immunocytochemistry.
  • CONCLUSIONS: The present study demonstrated that measurement of gelatinolytic activity by FIZ analysis of aspiration cytology samples may be useful for improving the cytological diagnosis of breast tumors.
  • [MeSH-major] Breast Neoplasms / enzymology. Gelatin / metabolism. Matrix Metalloproteinase 2 / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / enzymology. Biomarkers, Tumor / metabolism. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Ductal, Breast / enzymology. Carcinoma, Lobular / diagnosis. Carcinoma, Lobular / enzymology. Female. Fibrosarcoma / diagnosis. Fibrosarcoma / enzymology. Humans. Immunoenzyme Techniques. Neoplasm Invasiveness / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. GELATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16929121.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / gelatin film; 9000-70-8 / Gelatin; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


40. Aulmann S, Elsawaf Z, Penzel R, Schirmacher P, Sinn HP: Invasive tubular carcinoma of the breast frequently is clonally related to flat epithelial atypia and low-grade ductal carcinoma in situ. Am J Surg Pathol; 2009 Nov;33(11):1646-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive tubular carcinoma of the breast frequently is clonally related to flat epithelial atypia and low-grade ductal carcinoma in situ.
  • Low-grade precursor lesions, such flat epithelial atypia (FEA), low-grade ductal carcinoma in situ (lg-DCIS), and lobular neoplasia (LN) often coexist with invasive tubular carcinomas (TCs) of the breast.
  • Our data indicate, that in the majority of cases lg-DCIS and FEA are directly related to tubular breast cancer with a possible precursor role.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / pathology

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19675453.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Mitochondrial; 0 / DNA, Neoplasm
  •  go-up   go-down


41. Rüschoff J, Nagelmeier I, Baretton G, Dietel M, Höfler H, Schildhaus HU, Büttner R, Schlake W, Stoss O, Kreipe HH: [Her2 testing in gastric cancer. What is different in comparison to breast cancer?]. Pathologe; 2010 May;31(3):208-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Her2 testing in gastric cancer. What is different in comparison to breast cancer?].
  • Based on data from a large multicenter phase III trial (ToGA study) trastuzumab has very recently been approved by the EMEA for metastatic gastric cancer and adenocarcinoma of the gastro-esophageal junction.
  • However, testing of Her2 status by immunohistochemistry (IHC) differs from breast cancer in core aspects: 1.
  • Evaluation of Her2 in situ hybridization (ISH) is similar to breast cancer with ratio values of > or =2.0 indicating Her2 gene amplification.
  • In contrast to breast cancer, up to one-third of gastric cancers show a heterogeneous Her2 status both at IHC and ISH levels which favors bright field ISH over FISH.
  • [MeSH-major] Breast Neoplasms / genetics. Receptor, ErbB-2 / genetics. Stomach Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Algorithms. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Gene Amplification. Humans. In Situ Hybridization. In Situ Hybridization, Fluorescence. Neoplasm Metastasis


42. Tanner M, Hollmén M, Junttila TT, Kapanen AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E, Elenius K, Isola J: Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol; 2005 Feb;16(2):273-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: HER-2/neu gene amplification has predictive value in breast cancer patients responding to trastuzumab.
  • PATIENTS AND METHODS: The frequency of HER-2/neu and Topoisomerase IIalpha gene amplification was studied in adenocarcinomas of the stomach (n=131) and the gastroesophageal junction (n=100) by chromogenic in situ hybridization (CISH).
  • Sensitivity of a gastric cancer cell line N87 with HER-2/neu amplification to trastuzumab was studied by a cell viability assay and compared with that of a HER-2 amplified breast cancer cell line SKBR-3.
  • HER-2/neu amplification was more common in the intestinal histologic type of gastric cancer (21.5%) than in the diffuse (2%) or the mixed/anaplastic type (5%, P=0.0051), but it was not associated with gender, age at diagnosis or clinical stage.
  • HER-2/neu targeting antibody trastuzumab inhibited the growth of a p185(HER-2/neu) overexpressing gastric and breast carcinoma cell lines (N87 and SKBR-3) with equal efficacy.


43. Hameed O, Chhieng DC, Adams AL: Does using a higher cutoff for the percentage of positive cells improve the specificity of HER-2 immunohistochemical analysis in breast carcinoma? Am J Clin Pathol; 2007 Nov;128(5):825-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does using a higher cutoff for the percentage of positive cells improve the specificity of HER-2 immunohistochemical analysis in breast carcinoma?
  • Blinded to the HER-2 amplification status, 3 pathologists retrospectively reviewed HER-2-stained sections of breast carcinoma and considered cases to be positive for protein overexpression (3+) using 3 cutoff levels, 10%, 30%, and 50%, for the proportion of cells with intense uniform staining.
  • Of 98 cases, 27 (28%) were positive by fluorescence in situ hybridization (FISH), and 32 (33%), 28 (29%), and 26 (27%) were considered positive for overexpression using cutoffs of 10%, 30%, and 50%, respectively.
  • [MeSH-major] Adenocarcinoma / chemistry. Biomarkers, Tumor / analysis. Breast Neoplasms / chemistry. Receptor, ErbB-2 / analysis
  • [MeSH-minor] Cell Count. Female. Guidelines as Topic. Humans. Immunohistochemistry / methods. In Situ Hybridization, Fluorescence. Predictive Value of Tests. Reproducibility of Results. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17951206.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


44. Carvalho J, Fullen D, Lowe L, Su L, Ma L: The expression of CD23 in cutaneous non-lymphoid neoplasms. J Cutan Pathol; 2007 Sep;34(9):693-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In comparison, pagetoid Bowen's disease, melanoma in situ and sebaceous carcinoma exhibited negative staining.
  • In addition, CD23 reacted diffusely with cutaneous mucinous eccrine carcinoma in a manner similar to breast or colonic adenocarcinoma.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17696916.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, IgE
  •  go-up   go-down


45. Anderson WF, Devesa SS: In situ male breast carcinoma in the Surveillance, Epidemiology, and End Results database of the National Cancer Institute. Cancer; 2005 Oct 15;104(8):1733-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In situ male breast carcinoma in the Surveillance, Epidemiology, and End Results database of the National Cancer Institute.
  • BACKGROUND: In situ breast carcinoma is not so well characterized for men as for women.
  • METHODS: Therefore, the authors of the current study compared male and female in situ and invasive breast carcinomas in the Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute to document these patterns.
  • RESULTS: In situ breast carcinomas composed 9.4% of all male (n = 280 of 2984) and 11.9% of all female breast carcinomas (n = 53,928 of 454,405) during the years 1973-2001.
  • In situ rates rose 123% for men and 555% for women over this time period; whereas distant disease rates fell for both genders.
  • Median ages at diagnosis were 62 years for in situ and 68 years for invasive breast carcinoma among men, compared with 58 years for in situ and 62 years for invasive breast carcinoma among women.
  • Papillary in situ and invasive architectural types were more common among men than women.
  • Breast cancer-specific survival was similar among men and women, whereas overall survival was worse for men than women.
  • CONCLUSION: In situ male breast carcinoma is a rare disease, occurring at older ages and with different architectural types than its more common female counterpart.
  • Gender-specific histopathologic differences probably reflect anatomic differences among the normal female and vestigial male breast.
  • Rising in situ male breast carcinoma incidence rates over the past three decades suggest earlier detection over time, irrespective of mammography, because men do not participate in routine screening mammography.
  • [MeSH-major] Breast Neoplasms, Male / epidemiology. SEER Program / statistics & numerical data
  • [MeSH-minor] Adenocarcinoma, Mucinous / epidemiology. Aged. Aged, 80 and over. Breast Neoplasms / epidemiology. Carcinoma in Situ / epidemiology. Female. Humans. Incidence. Male. Middle Aged. Neoplasm Invasiveness. Neoplasms, Ductal, Lobular, and Medullary / epidemiology. Risk Factors. Survival Rate. United States / epidemiology


46. Rosen EL, Turkington TG, Soo MS, Baker JA, Coleman RE: Detection of primary breast carcinoma with a dedicated, large-field-of-view FDG PET mammography device: initial experience. Radiology; 2005 Feb;234(2):527-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of primary breast carcinoma with a dedicated, large-field-of-view FDG PET mammography device: initial experience.
  • PURPOSE: To prospectively assess a dedicated, large field of view positron emission tomography (PET) mammographic device for imaging primary breast carcinoma.
  • One hour after administration of 2.0-2.5 mCi (74.0-93.5 MBq) of fluorodeoxyglucose, 5-minute PET mammography of the affected breast was performed.
  • CONCLUSION: These pilot data suggest that PET mammography can demonstrate small primary breast malignancies.
  • [MeSH-major] Breast Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography / instrumentation
  • [MeSH-minor] Adenocarcinoma / radionuclide imaging. Adult. Aged. Biopsy. Breast Diseases / radionuclide imaging. Calcinosis / radionuclide imaging. Carcinoma in Situ / radionuclide imaging. Carcinoma, Ductal, Breast / radionuclide imaging. Carcinoma, Lobular / radionuclide imaging. Female. Humans. Mammography. Middle Aged. Predictive Value of Tests. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2005.
  • (PMID = 15671006.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


47. Belguise K, Guo S, Yang S, Rogers AE, Seldin DC, Sherr DH, Sonenshein GE: Green tea polyphenols reverse cooperation between c-Rel and CK2 that induces the aryl hydrocarbon receptor, slug, and an invasive phenotype. Cancer Res; 2007 Dec 15;67(24):11742-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Exposure to and bioaccumulation of lipophilic environmental pollutants, such as polycyclic aromatic hydrocarbons (PAHs), has been implicated in breast cancer.
  • Here, we show that green tea prevents or reverses loss of the epithelial marker E-cadherin on the surface of DMBA-induced in situ cancers.
  • [MeSH-minor] 9,10-Dimethyl-1,2-benzanthracene. Adenocarcinoma / chemically induced. Adenocarcinoma / genetics. Adenocarcinoma / pathology. Animals. Beverages. Carcinoma in Situ / chemically induced. Carcinoma in Situ / genetics. Carcinoma in Situ / pathology. Female. Neoplasm Invasiveness / genetics. Phenotype. Polyphenols. Rats. Rats, Sprague-Dawley

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18089804.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA71796; United States / NIEHS NIH HHS / ES / P01 ES11624
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Flavonoids; 0 / Phenols; 0 / Polyphenols; 0 / Proto-Oncogene Proteins c-rel; 0 / Transcription Factors; 0 / snail family transcription factors; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; EC 2.7.11.1 / Casein Kinase II
  •  go-up   go-down


48. Rogalska A, Szwed M, Jóźwiak Z: Aclarubicin-induced apoptosis and necrosis in cells derived from human solid tumours. Mutat Res; 2010 Jul 19;700(1-2):1-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study, we investigated the response of A549 (non-small cell lung-cancer), HepG2 (human hepatoma) and MCF-7 (human breast adenocarcinoma) cell lines to treatment with aclarubicin (ACL).
  • [MeSH-minor] Caspase 3 / metabolism. Caspase 8 / metabolism. DNA Fragmentation / drug effects. Dose-Response Relationship, Drug. Drug Screening Assays, Antitumor. Humans. In Situ Nick-End Labeling. Poly(ADP-ribose) Polymerases. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20399885.001).
  • [ISSN] 0027-5107
  • [Journal-full-title] Mutation research
  • [ISO-abbreviation] Mutat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 74KXF8I502 / Aclarubicin; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 8
  •  go-up   go-down


49. Obaidat NA, Awamleh AA, Ghazarian DM: Adenocarcinoma in situ arising in a tubulopapillary apocrine hidradenoma of the peri-anal region. Eur J Dermatol; 2006 Sep-Oct;16(5):576-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma in situ arising in a tubulopapillary apocrine hidradenoma of the peri-anal region.
  • Histologically, the excised lesion showed features of tubulopapillary apocrine hidradenoma, with an area showing features of carcinoma in situ.
  • The lesion also had papillary and cribriform growth patterns, reminiscent of breast lesions.
  • To the best of our knowledge, this is the first description of a peri-anal adenocarcinoma in situ arising in a tubulopapillary apocrine hidradenoma.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma, Sweat Gland / pathology. Anus Neoplasms / pathology. Carcinoma in Situ / pathology. Sweat Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17101482.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  •  go-up   go-down


50. Wasif N, Garreau J, Terando A, Kirsch D, Mund DF, Giuliano AE: MRI versus ultrasonography and mammography for preoperative assessment of breast cancer. Am Surg; 2009 Oct;75(10):970-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MRI versus ultrasonography and mammography for preoperative assessment of breast cancer.
  • Mammography and ultrasonography are traditional for preoperative estimation of breast cancer size; magnetic resonance imaging (MRI) is more recent but not as well studied.
  • We compared ultrasonography, mammography, and MRI for preoperative imaging of primary breast cancer presenting as a mass in patients treated at our center over a 2-year period.
  • Of the 61 breast cancers with all three imaging modalities performed, 52 were infiltrating ductal cancer, 5 were infiltrating lobular cancer, 2 were ductal carcinoma in situ, and 2 were other histologic types.
  • We conclude that MRI is more accurate than either ultrasonography or mammography for assessment of the size of primary breast cancer presenting as a mass.
  • [MeSH-major] Adenocarcinoma / diagnosis. Breast Neoplasms / diagnosis. Magnetic Resonance Imaging. Mammography. Ultrasonography, Mammary


51. Pohl H, Welch HG: The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst; 2005 Jan 19;97(2):142-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence.
  • BACKGROUND: The incidence of esophageal adenocarcinoma is rising dramatically.
  • METHODS: We used the National Cancer Institute's Surveillance, Epidemiology, and End Results database to extract information on incidence, stage distribution, and disease-specific mortality for esophageal adenocarcinoma as well as information on related cancers.
  • RESULTS: From 1975 to 2001, the incidence of esophageal adenocarcinoma rose approximately sixfold in the United States (from 4 to 23 cases per million), a relative increase greater than that for melanoma, breast, or prostate cancer.
  • The only location with increased incidence is the lower third of the esophagus-the site where adenocarcinoma typically arises.
  • Because there has been little change in the proportion of patients found with in situ or localized disease at diagnosis since 1975 (from 25% to 31%) and because esophageal adenocarcinoma mortality has increased more than sevenfold (from 2 to 15 deaths per million), overdiagnosis can be excluded as an explanation for the rise in incidence.
  • CONCLUSION: The rising incidence of esophageal adenocarcinoma represents a real increase in disease burden.
  • [MeSH-major] Adenocarcinoma / classification. Adenocarcinoma / epidemiology. Esophageal Neoplasms / classification. Esophageal Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Classification / methods. Confounding Factors (Epidemiology). Cost of Illness. Cross-Sectional Studies. Diagnosis, Differential. Diagnostic Errors. Female. Humans. Incidence. Male. Middle Aged. Risk Factors. SEER Program. United States / epidemiology


52. Kazakov DV, Suster S, LeBoit PE, Calonje E, Bisceglia M, Kutzner H, Rütten A, Mentzel T, Schaller J, Zelger B, Baltaci M, Leivo I, Rose C, Fukunaga M, Simpson RH, Yang Y, Carlson JA, Cavazza A, Hes O, Mukensnabl P, Vanecek T, Fidalgo A, Pizinger K, Michal M: Mucinous carcinoma of the skin, primary, and secondary: a clinicopathologic study of 63 cases with emphasis on the morphologic spectrum of primary cutaneous forms: homologies with mucinous lesions in the breast. Am J Surg Pathol; 2005 Jun;29(6):764-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous carcinoma of the skin, primary, and secondary: a clinicopathologic study of 63 cases with emphasis on the morphologic spectrum of primary cutaneous forms: homologies with mucinous lesions in the breast.
  • Our aim was fully to characterize the clinicopathologic spectrum and compare it with that seen in the breast.
  • Most lesions seem to originate from in situ lesions that may represent, using mammary pathology terminology, ductal hyperplasia, atypical ductal hyperplasia, or ductal carcinoma in situ or a combination of the three.
  • Inverse cell polarity appears to facilitate the progression of the changes similar to lesions in the breast.
  • The presence of an in situ component defines the neoplasm as primary cutaneous, but its absence does not exclude the diagnosis; although for such neoplasms, full clinical assessment is essential.
  • Mammary mucinous carcinoma involving the skin: all patients presented with lesions on chest wall, breast, axilla, and these locations can serve as clue to the breast origin.
  • Microscopically, cutaneous lesions were of both pure and mixed type, and this correlated with the primary in the breast.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Breast Neoplasms / pathology. Intestinal Neoplasms / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast Neoplasms, Male / pathology. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15897743.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Bendrik C, Dabrosin C: Estradiol increases IL-8 secretion of normal human breast tissue and breast cancer in vivo. J Immunol; 2009 Jan 1;182(1):371-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estradiol increases IL-8 secretion of normal human breast tissue and breast cancer in vivo.
  • IL-8 or CXCL8 has been associated with tumor angiogenesis, metastasis, and poor prognosis in breast cancer.
  • Estrogen is crucial in breast carcinogenesis and tumor progression.
  • Whether sex steroids affect IL-8 secretion of normal breast tissue or breast cancer is not known.
  • We used microdialysis to sample IL-8 in normal human breast tissue in situ in pre- and postmenopausal women, preoperatively in breast cancers of women, and in experimental breast cancer in mice.
  • We found a significant positive correlation between IL-8 and estradiol in normal breast tissue and hormone-dependent breast cancer in vivo.
  • Ex vivo, estradiol exposure increased the IL-8 secretion of normal whole breast tissue in culture.
  • In experimental breast cancer, estradiol increased IL-8 whereas the anti-estrogen tamoxifen inhibited the secretion of IL-8 both in vitro and extracellularly in vivo in tumors of nude mice.
  • Our results strongly suggest that estradiol has a critical role in the regulation of IL-8 in normal human breast tissue and human breast cancer.
  • IL-8 may present a novel therapeutic target for estrogen driven breast carcinogenesis and tumor progression.
  • [MeSH-major] Adenocarcinoma / secretion. Breast / immunology. Breast / secretion. Breast Neoplasms / secretion. Estradiol / physiology. Interleukin-8 / secretion. Up-Regulation / immunology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19109168.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-8; 4TI98Z838E / Estradiol
  •  go-up   go-down


54. Uzan C, Andre F, Scott V, Laurent I, Azria E, Suciu V, Balleyguier C, Lacroix L, Delaloge S, Vielh P: Fine-needle aspiration for nucleic acid-ased molecular analyses in breast cancer. Cancer; 2009 Feb 25;117(1):32-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration for nucleic acid-ased molecular analyses in breast cancer.
  • METHODS: Ultrasound- or palpation-guided FNAC was performed in 124 consecutive patients who had nodular breast lesions.
  • For malignant lesions, the authors attempted to correlate estrogen receptor 1 (ESR1) and HER-2 (c-erb-B2) mRNA expression measured by real-time quantitative polymerase chain reaction with estrogen receptor and HER-2 detection obtained by immunohistochemistry (IHC) and/or fluorescent in situ hybridization (FISH) on the surgical specimen.
  • The most significant predictors of quality and quantity of mRNA were the cytopathologist who sampled the tumors and a diagnosis of cancer versus benign lesion.
  • CONCLUSIONS: In 70% of cases, FNAC of breast lesions in well trained hands allowed the extraction of mRNA suitable for gene expression analysis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biopsy, Fine-Needle. Breast Neoplasms / diagnosis. RNA, Messenger / isolation & purification
  • [MeSH-minor] Estrogen Receptor alpha / biosynthesis. Estrogen Receptor alpha / genetics. Female. Gene Expression Profiling. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Middle Aged. Receptor, ErbB-2 / biosynthesis. Receptor, ErbB-2 / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 American Cancer Society.
  • (PMID = 19347827.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / RNA, Messenger; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


55. Trastour C, Benizri E, Ettore F, Ramaioli A, Chamorey E, Pouysségur J, Berra E: HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome. Int J Cancer; 2007 Apr 1;120(7):1451-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome.
  • The aim of our study was to evaluate the impact of HIF-1alpha and CA IX (carbonic anhydrase IX) (one of its target genes) expression on prognosis and treatment outcome of patients with breast cancer.
  • Afterwards, the immunohistochemical staining of HIF-1alpha and CA IX was evaluated in 132 invasive breast carcinomas with a 10-year follow-up, and correlated to classical clinicopathological parameters and response to adjuvant therapy.
  • Statistically significant association was found between HIF-1alpha or CA IX staining and the grade, hormonal receptors loss and the presence of carcinoma in situ.
  • Overexpression of HIF-1alpha and CA IX correlates with a poor prognosis in breast cancer.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Breast Neoplasms / metabolism. Carbonic Anhydrases / metabolism. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Animals. Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / metabolism. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / pathology. Carcinoma, Medullary / drug therapy. Carcinoma, Medullary / metabolism. Carcinoma, Medullary / pathology. Chemotherapy, Adjuvant. Female. Humans. Immunoenzyme Techniques. Male. Mice. Mice, Nude. Middle Aged. Neoplasm Invasiveness. Prognosis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17245699.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / HIF1A protein, human; 0 / Hif1a protein, mouse; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases
  •  go-up   go-down


56. Dubois V, Delort L, Mishellany F, Jarde T, Billard H, Lequeux C, Damour O, Penault-Llorca F, Vasson MP, Caldefie-Chezet F: Zinc-alpha2-glycoprotein: a new biomarker of breast cancer? Anticancer Res; 2010 Jul;30(7):2919-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Zinc-alpha2-glycoprotein: a new biomarker of breast cancer?
  • BACKGROUND/AIM: Obesity increases the risk of breast cancer.
  • We have shown that two major adipokines, leptin and adiponectin, were expressed in mammary adenocarcinoma.
  • PATIENTS AND METHODS: Here, we evaluated zinc-alpha2-glycoprotein (ZAG) expression in tumor (n=55) and healthy (n=6) breast tissue by immunohistochemistry and examined whether it was correlated with that of major adipokines, usual tumor biomarkers (sex steroids receptors, i.e. estrogen (ER) and progesterone; Ki-67; cErb2), or apoptosis markers (Bcl2 and Bax).
  • CONCLUSION: These preliminary results suggest both a relationship between ZAG expression and pathways involving adipokines or estrogen and that ZAG may be a potential breast cancer biomarker.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Breast Neoplasms / metabolism. Carrier Proteins / biosynthesis. Glycoproteins / biosynthesis
  • [MeSH-minor] Adiponectin / biosynthesis. Adult. Aged. Aged, 80 and over. Apoptosis / physiology. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Case-Control Studies. Female. Humans. Immunohistochemistry. Leptin / biosynthesis. Middle Aged. Proto-Oncogene Proteins c-bcl-2 / biosynthesis. bcl-2-Associated X Protein / biosynthesis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20683033.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / ADIPOQ protein, human; 0 / AZGP1 protein, human; 0 / Adiponectin; 0 / BAX protein, human; 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Glycoproteins; 0 / Leptin; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2-Associated X Protein
  •  go-up   go-down


57. Bhargava R, Gerald WL, Li AR, Pan Q, Lal P, Ladanyi M, Chen B: EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol; 2005 Aug;18(8):1027-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations.
  • The human epidermal growth factor receptor (HER) family of receptor tyrosine kinase has been extensively studied in breast cancer; however, systematic studies of EGFR gene amplification and protein overexpression in breast carcinoma are lacking.
  • We studied EGFR gene amplification by chromogenic in situ hybridization (CISH) and protein expression by immunohistochemistry in 175 breast carcinomas, using tissue microarrays.
  • HER-2 gene amplification by fluorescence in situ hybridization (FISH) and protein overexpression by immunohistochemistry were also studied.
  • The EGFR mRNA level, based on Affymetrix U133 chip hybridization data, was increased relative to other breast cancer samples in three of the five tumors showing gene amplification.
  • Approximately 6% of breast carcinomas show EGFR amplification with EGFR protein overexpression and may be candidates for trials of EGFR-targeted antibodies or small inhibitory molecules.
  • [MeSH-major] Breast Neoplasms / pathology. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. DNA Mutational Analysis / methods. Female. Gene Amplification. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. In Situ Hybridization / methods. In Situ Hybridization, Fluorescence. Lung Neoplasms / genetics. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Middle Aged. Mutation. RNA, Messenger / genetics. RNA, Messenger / metabolism. Receptor, ErbB-2 / genetics. Tissue Array Analysis


58. Ting AY, Kimler BF, Fabian CJ, Petroff BK: Characterization of a preclinical model of simultaneous breast and ovarian cancer progression. Carcinogenesis; 2007 Jan;28(1):130-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of a preclinical model of simultaneous breast and ovarian cancer progression.
  • Women at increased risk for breast cancer are often also at increased risk for ovarian cancer, reflecting common risk factors and intertwined etiologies for both diseases.
  • Unlike breast cancer prevention, primary ovarian cancer prevention has been impractical due to the low incidence, lack of risk and response biomarkers and difficulties in sampling ovarian tissue.
  • Challenges in the development of ovarian cancer prevention drugs, however, may be circumvented through the development of breast cancer prevention strategies that simultaneously decrease ovarian cancer.
  • All E2/DMBA-treated rats had mammary hyperplasia, atypia, ductal carcinoma in situ and/or invasive adenocarcinoma, while 50% also developed preneoplastic changes in the ovary (ovarian epithelial and stromal hyperplasia and inclusion cyst formation).
  • This combined breast and ovarian cancer rat model (systemic E2 treatment and local ovarian DMBA) may be useful for future dual target breast and ovarian cancer prevention studies.
  • [MeSH-minor] 9,10-Dimethyl-1,2-benzanthracene / toxicity. Adenocarcinoma / chemically induced. Adenocarcinoma / pathology. Alkylating Agents / toxicity. Animals. Carcinogens / toxicity. Carcinoma, Intraductal, Noninfiltrating / chemically induced. Carcinoma, Intraductal, Noninfiltrating / pathology. Cell Proliferation / drug effects. Cells, Cultured. Cyclooxygenase 2 / metabolism. Disease Progression. Epithelium / drug effects. Estrogen Receptor alpha / metabolism. Estrogens / toxicity. Female. Hyperplasia / chemically induced. Hyperplasia / pathology. Immunoenzyme Techniques. Ki-67 Antigen / metabolism. Methylnitrosourea / toxicity. Precancerous Conditions. Rats. Rats, Inbred F344

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • Hazardous Substances Data Bank. N-NITROSO-N-METHYLUREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16891317.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA089019
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Alkylating Agents; 0 / Carcinogens; 0 / Estrogen Receptor alpha; 0 / Estrogens; 0 / Ki-67 Antigen; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; 684-93-5 / Methylnitrosourea; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


59. Levine P, Simsir A, Cangiarella J: Management issues in breast lesions diagnosed by fine-needle aspiration and percutaneous core breast biopsy. Am J Clin Pathol; 2006 Jun;125 Suppl:S124-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management issues in breast lesions diagnosed by fine-needle aspiration and percutaneous core breast biopsy.
  • The use offine-needle aspiration biopsy or percutaneous core needle biopsy to diagnose breast lesions has increased during the past few decades.
  • Although the benefits of these procedures are well known, controversies remain about the management of certain categories of breast lesions detected by these methods.
  • This article discusses the management issues in categories of breast lesions, including papillary lesions, atypical lobular hyperplasia and lobular carcinoma in situ, and mucinous lesions diagnosed by the preoperative techniques of aspiration or core biopsy.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Biopsy, Fine-Needle / methods. Breast / pathology. Breast Neoplasms / pathology. Carcinoma, Lobular / pathology. Carcinoma, Papillary / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16830962.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 139
  •  go-up   go-down


60. Kajiwara H, Kumaki N, Hirabayashi K, Miyazawa M, Nakamura N, Hirasawa T, Muramatsu T, Mikami M, Yasuda M, Osamura RY: A case of oncocytic carcinoma of the endometrium. Arch Gynecol Obstet; 2009 May;279(5):733-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report an unusual case of endometrial adenocarcinoma in a 80-year-old woman who underwent mastectomy for breast cancer at 68 years of age.
  • Components of the carcinoma were focally observed in situ.
  • Distinguishing between primary uterine neoplasm and carcinoma caused by metastasis of breast cancer appears important.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Neoplasms, Second Primary / pathology

  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18795309.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


61. Kammori M, Izumiyama N, Hashimoto M, Nakamura K, Okano T, Kurabayashi R, Naoki H, Honma N, Ogawa T, Kaminishi M, Takubo K: Expression of human telomerase reverse transcriptase gene and protein, and of estrogen and progesterone receptors, in breast tumors: preliminary data from neo-adjuvant chemotherapy. Int J Oncol; 2005 Nov;27(5):1257-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of human telomerase reverse transcriptase gene and protein, and of estrogen and progesterone receptors, in breast tumors: preliminary data from neo-adjuvant chemotherapy.
  • In situ detection of hTERT will aid in determining the localization of telomerase-positive cells.
  • The aim of this study was to detect expression of hTERT mRNA, hTERT protein, estrogen receptor (ER) and progesterone receptor (PR) in paraffin-embedded breast tissue samples and to investigate the relationship between hTERT expression and various clinicopathological parameters in breast tumorigenesis.
  • We used in situ hybridization (ISH) to examine hTERT gene expression, and immunohistochemistry (IHC) to examine expression of hTERT protein, ER and PR, in breast tissues including 64 adenocarcinomas, 2 phyllode tumors and their adjacent normal breast tissues. hTERT gene expression was detected by ISH in 56 (88%) carcinomas, but in neither of the 2 phyllode tumors. hTERT protein expression was detected by IHC in 52 (81%) carcinomas, but in neither of the 2 phyllode tumors.
  • In 4 cases of breast carcinoma that strongly expressed hTERT gene and protein before treatment, neo-adjuvant chemotherapy led to disappearance of gene and protein expression in all cases.
  • There was a strong correlation between detection of hTERT gene expression by ISH and of hTERT protein by ICH in tissue specimens from breast tumors.
  • These results suggest that detection of hTERT protein by ICH can be used to distinguish breast cancers as a potential diagnostic and therapeutic marker.
  • [MeSH-major] Adenocarcinoma / genetics. Breast Neoplasms / genetics. DNA-Binding Proteins / biosynthesis. DNA-Binding Proteins / genetics. Receptors, Estrogen / biosynthesis. Receptors, Progesterone / biosynthesis. Telomerase / biosynthesis. Telomerase / genetics
  • [MeSH-minor] Biomarkers, Tumor / analysis. Cell Transformation, Neoplastic. Female. Gene Expression Profiling. Humans. In Situ Hybridization. Middle Aged. Neoadjuvant Therapy. Phyllodes Tumor. Prognosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16211220.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


62. Tsiambas E, Karameris A, Dervenis C, Lazaris AC, Giannakou N, Gerontopoulos K, Patsouris E: HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis. JOP; 2006;7(3):283-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis.
  • CONTEXT: HER2/neu overexpression is observed in many cancers including pancreatic ductal adenocarcinoma.
  • Immunohistochemistry (clone TAB 250) and chromogenic (HER2/neu amplification Spot Light kit) in situ hybridization protocols were performed.
  • In contrast to breast cancer, protein overexpression does not predict this specific gene deregulation mechanism.
  • Furthermore, evaluation of HER2/neu protein expression based on digital image analysis and not only on conventional eye microscopy improves the accuracy and reliability of immunohistochemical estimation, although that does not demonstrate clinical significance and prognostic value in pancreatic ductal adenocarcinoma.
  • [MeSH-major] Carcinoma, Ductal, Breast / metabolism. Gene Amplification. Genes, erbB-2. Pancreatic Neoplasms / metabolism. Receptor, ErbB-2 / metabolism
  • [MeSH-minor] Aged. Aneuploidy. Chromosomes, Human, Pair 17. Female. Humans. Image Processing, Computer-Assisted. Immunohistochemistry / methods. In Situ Hybridization. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Reproducibility of Results. Staining and Labeling


63. Sahoo S, Recant WM: Triad of columnar cell alteration, lobular carcinoma in situ, and tubular carcinoma of the breast. Breast J; 2005 Mar-Apr;11(2):140-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Triad of columnar cell alteration, lobular carcinoma in situ, and tubular carcinoma of the breast.
  • Columnar cell alteration in the breast encompasses a spectrum of pathologic changes ranging from simple columnar cell change to more complex columnar cell hyperplasia with and without atypia to in situ carcinoma, often with a micropapillary architecture.
  • For reasons that remain unclear, the columnar cell lesions are associated with tubular carcinomas and lobular carcinoma in situ.
  • Therefore it is important to be familiar with the spectrum of changes and the associated lesions, especially in breast core biopsies for further management.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Carcinoma in Situ / pathology. Fibrocystic Breast Disease / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Adult. Breast / pathology. Calcinosis / pathology. Diagnosis, Differential. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15730461.001).
  • [ISSN] 1075-122X
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Anagnostou VK, Lowery FJ, Zolota V, Tzelepi V, Gopinath A, Liceaga C, Panagopoulos N, Frangia K, Tanoue L, Boffa D, Gettinger S, Detterbeck F, Homer RJ, Dougenis D, Rimm DL, Syrigos KN: High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology. BMC Cancer; 2010;10:186
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AQUA(R), a fluorescent-based method for analysis of in situ protein expression, was used to measure Bcl-2 protein levels and classify tumors by Bcl-2 expression in a cohort of 180 NSCLC patients.
  • [MeSH-major] Adenocarcinoma / chemistry. Biomarkers, Tumor / analysis. Carcinoma, Large Cell / chemistry. Carcinoma, Non-Small-Cell Lung / chemistry. Carcinoma, Squamous Cell / chemistry. Lung Neoplasms / chemistry. Proto-Oncogene Proteins c-bcl-2 / analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lung Cancer. 2006 May;52(2):241-7 [16529843.001]
  • [Cites] Leuk Res. 2006 Mar;30(3):322-31 [16213584.001]
  • [Cites] Oncogene. 2006 Aug 7;25(34):4697-705 [16892083.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 May 1;50(1):13-8 [11316541.001]
  • [Cites] Hum Pathol. 2002 Jan;33(1):105-10 [11823980.001]
  • [Cites] J Clin Oncol. 2002 Nov 1;20(21):4285-91 [12409326.001]
  • [Cites] Nat Med. 2002 Nov;8(11):1323-7 [12389040.001]
  • [Cites] Chest. 2003 Jun;123(6):1858-67 [12796161.001]
  • [Cites] Cancer. 2003 Jul 1;98(1):135-43 [12833466.001]
  • [Cites] Br J Cancer. 2003 Jul 7;89(1):55-64 [12838300.001]
  • [Cites] Lancet. 2003 Aug 9;362(9382):433-9 [12927430.001]
  • [Cites] Eur J Surg Oncol. 2003 Oct;29(8):654-7 [14511612.001]
  • [Cites] Lung Cancer. 2003 Dec;42(3):275-81 [14644514.001]
  • [Cites] Histopathology. 2004 Jan;44(1):54-63 [14717670.001]
  • [Cites] Anticancer Res. 2004 May-Jun;24(3b):1925-8 [15274378.001]
  • [Cites] Nature. 1990 Nov 22;348(6299):334-6 [2250705.001]
  • [Cites] Cell. 1993 Aug 27;74(4):609-19 [8358790.001]
  • [Cites] Cancer Res. 1994 Jan 1;54(1):256-60 [8261449.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 1994 Aug 30;345(1313):289-95 [7846127.001]
  • [Cites] Annu Rev Immunol. 1995;13:513-43 [7612233.001]
  • [Cites] Hum Pathol. 1995 Nov;26(11):1227-32 [7590697.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9545-52 [8790367.001]
  • [Cites] Science. 1997 Dec 12;278(5345):1966-8 [9395403.001]
  • [Cites] Virchows Arch. 1998 May;432(5):441-4 [9645443.001]
  • [Cites] Trends Cell Biol. 1998 Aug;8(8):324-30 [9704409.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1305-8 [9721089.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1322-6 [9735050.001]
  • [Cites] Lung Cancer. 1998 Dec;22(3):181-90 [10048471.001]
  • [Cites] Br J Cancer. 1999 Feb;79(5-6):952-8 [10070896.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7252-9 [15534099.001]
  • [Cites] Clin Cancer Res. 2004 Nov 15;10(22):7662-70 [15569999.001]
  • [Cites] Nature. 2005 Jun 2;435(7042):677-81 [15902208.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5554-60 [15994927.001]
  • [Cites] J Natl Cancer Inst. 2005 Dec 21;97(24):1808-15 [16368942.001]
  • [Cites] Cancer Cell. 2006 Nov;10(5):389-99 [17097561.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] Oncogene. 2007 Feb 1;26(5):652-61 [16909121.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1176-83 [17283153.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Mar;15(1):31-7 [17536304.001]
  • [Cites] Chest. 2007 Sep;132(3 Suppl):277S-289S [17873174.001]
  • [Cites] J Clin Oncol. 2008 Feb 20;26(6):870-6 [18281659.001]
  • [Cites] IUBMB Life. 2008 Jun;60(6):390-7 [18425793.001]
  • [Cites] Breast Cancer Res. 2008;10(2):R35 [18430249.001]
  • [Cites] Tumori. 2008 May-Jun;94(3):398-405 [18705409.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4180-8 [18757333.001]
  • [Cites] Am J Respir Cell Mol Biol. 2009 Feb;40(2):135-46 [18676776.001]
  • [Cites] J Thorac Oncol. 2009 Apr;4(4):486-91 [19240654.001]
  • [Cites] Lung Cancer. 2009 Sep;65(3):377-82 [19150580.001]
  • [Cites] Int J Clin Pract. 2006 Jun;60(6):675-82 [16805752.001]
  • (PMID = 20459695.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-2
  • [Other-IDs] NLM/ PMC2875218
  •  go-up   go-down


65. Khalbuss WE, Ambaye A, Goodison S, Loya A, Masood S: Papillary carcinoma of the breast in a male patient with a treated prostatic carcinoma diagnosed by fine-needle aspiration biopsy: a case report and review of the literature. Diagn Cytopathol; 2006 Mar;34(3):214-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary carcinoma of the breast in a male patient with a treated prostatic carcinoma diagnosed by fine-needle aspiration biopsy: a case report and review of the literature.
  • Papillary carcinoma of the male breast is very rare.
  • In this case report, we describe the cytologic, histologic, immunohistochemical, and radiological findings of a papillary carcinoma of male breast.
  • A 67-yr-old man, who had a previous history of prostatic adenocarcinoma, presented with a retroareolar painless mass.
  • There was no known history of breast cancer in his family.
  • A diagnosis of papillary lesion favoring papillary carcinoma was rendered.
  • The patient underwent lumpectomy, which showed a moderately differentiated infiltrating papillary carcinoma with adjacent areas of ductal carcinoma in situ.
  • FNAB is a useful technique in identifying male breast carcinoma.
  • [MeSH-major] Adenocarcinoma / therapy. Breast Neoplasms, Male / pathology. Carcinoma, Papillary / pathology. Neoplasms, Second Primary / pathology. Prostatic Neoplasms / therapy
  • [MeSH-minor] Aged. Biopsy, Fine-Needle. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Mammaglobin A. Neoplasm Metastasis. Neoplasm Proteins / analysis. Prostate-Specific Antigen / analysis. Uteroglobin / analysis

  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 Wiley-Liss, Inc.
  • [Cites] Int J Cancer. 1996 Feb 8;65(4):446-9 [8621225.001]
  • [Cites] Cancer Res. 1995 Mar 1;55(5):1002-5 [7866981.001]
  • [Cites] Pathology. 1997 Feb;29(1):2-6 [9094169.001]
  • [Cites] J Mol Med (Berl). 1997 Oct;75(10):758-61 [9383000.001]
  • [Cites] Indian J Pathol Microbiol. 1998 Jan;41(1):103-6 [9581085.001]
  • [Cites] Cancer. 1998 Aug 1;83(3):498-509 [9690543.001]
  • [Cites] Acta Cytol. 1999 Sep-Oct;43(5):767-70 [10518128.001]
  • [Cites] Cancer. 1962 May-Jun;15:444-55 [14459407.001]
  • [Cites] Breast J. 2003 May-Jun;9(3):208-12 [12752629.001]
  • [Cites] Diagn Cytopathol. 2003 Jun;28(6):329-34 [12768640.001]
  • [Cites] Arch Pathol Lab Med. 1986 Mar;110(3):189-91 [3080975.001]
  • [Cites] Tumori. 1986 Feb 28;72(1):105-8 [3952817.001]
  • [Cites] Diagn Cytopathol. 1991;7(6):581-90 [1769286.001]
  • [Cites] Am J Epidemiol. 1992 Apr 1;135(7):734-48 [1350708.001]
  • [Cites] Int J Cancer. 1993 Jan 21;53(2):269-77 [8425764.001]
  • [Cites] Acta Cytol. 1993 Sep-Oct;37(5):721-4 [8362586.001]
  • [Cites] Diagn Cytopathol. 1994;10(4):336-41 [7924806.001]
  • [Cites] Cancer Res. 1996 Feb 15;56(4):860-5 [8631025.001]
  • (PMID = 16548002.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA108597
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Number-of-references] 18
  • [Other-IDs] NLM/ NIHMS399894; NLM/ PMC3428056
  •  go-up   go-down


66. Trop I, David J, Lalonde L: Breast cancer staging: the role of the radiologist. Can Assoc Radiol J; 2005 Dec;56(5):324-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer staging: the role of the radiologist.
  • The role of the breast radiologist has evolved over the past years, with an increasing involvement in patient care.
  • This article reviews the elements of investigation that are important to the surgeon and oncologist in optimizing care for the newly diagnosed breast cancer patient, with the 6th edition of the TNM classification of the American Joint Committee on Cancer used as a reference.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / pathology. Carcinoma in Situ / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Lobular / pathology. Lymph Nodes / pathology. Neoplasm Staging / methods
  • [MeSH-minor] Adenocarcinoma / pathology. Aged. Breast Diseases / pathology. Diagnosis, Differential. Female. Humans. Lymphatic Metastasis / diagnosis. Lymphatic Metastasis / pathology. Magnetic Resonance Imaging. Mammography. Middle Aged. Nipples / pathology. Prognosis. Risk Factors. Sensitivity and Specificity. Sentinel Lymph Node Biopsy. Ultrasonography, Mammary

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16579027.001).
  • [ISSN] 0846-5371
  • [Journal-full-title] Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes
  • [ISO-abbreviation] Can Assoc Radiol J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Canada
  • [Number-of-references] 15
  •  go-up   go-down


67. Otsuki Y, Yamada M, Shimizu S, Suwa K, Yoshida M, Tanioka F, Ogawa H, Nasuno H, Serizawa A, Kobayashi H: Solid-papillary carcinoma of the breast: clinicopathological study of 20 cases. Pathol Int; 2007 Jul;57(7):421-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid-papillary carcinoma of the breast: clinicopathological study of 20 cases.
  • The purpose of the present paper was to evaluate the clinicopathological and biological features of 20 Japanese patients with solid-papillary carcinoma of the breast (SPC) or SPC associated with invasive breast cancer.
  • The incidence of SPC among all the breast cancers treated at two institutions was 1.1% and 1.7%, respectively.
  • When all the cases were classified and analyzed according to both the 2002 tumor node metastasis (TNM) classification system and the Nottingham histological grade, SPC patients, even those with invasive cancers, seemed to have longer disease-free survival compared to patients with the other invasive breast cancers of matching grade and stage.
  • Clinicopathologically, SPC could be regarded as a separate type of ductal carcinoma in situ.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / chemistry. Adenocarcinoma, Mucinous / classification. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Carcinoma, Neuroendocrine / chemistry. Carcinoma, Neuroendocrine / classification. Carcinoma, Neuroendocrine / pathology. Carcinoma, Neuroendocrine / surgery. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasms, Multiple Primary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17587241.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


68. Khayat AS, Guimarães AC, Calcagno DQ, Seabra AD, Lima EM, Leal MF, Faria MH, Rabenhorst SH, Assumpção PP, Demachki S, Smith MA, Burbano RR: Interrelationship between TP53 gene deletion, protein expression and chromosome 17 aneusomy in gastric adenocarcinoma. BMC Gastroenterol; 2009;9:55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interrelationship between TP53 gene deletion, protein expression and chromosome 17 aneusomy in gastric adenocarcinoma.
  • BACKGROUND: This study evaluates the existence of numerical alterations of chromosome 17 and TP53 gene deletion in gastric adenocarcinoma.
  • METHODS: Dual-color fluorescence in situ hybridization and immunostaining were performed in twenty gastric cancer samples of individuals from Northern Brazil.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosome Aberrations. Chromosomes, Human, Pair 17 / genetics. Gene Deletion. Gene Expression Regulation, Neoplastic / genetics. Stomach Neoplasms / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adult. Aged. Alleles. Brazil. Breast Neoplasms / genetics. Breast Neoplasms / pathology. Case-Control Studies. Female. Humans. In Situ Hybridization, Fluorescence. Loss of Heterozygosity / genetics. Male. Middle Aged

  • Genetic Alliance. consumer health - Chromosome 17, Deletion.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2000 Sep;37(3):241-9 [10971700.001]
  • [Cites] Cancer Genet Cytogenet. 2009 Apr 1;190(1):1-7 [19264226.001]
  • [Cites] Hum Mutat. 2003 Mar;21(3):258-70 [12619111.001]
  • [Cites] Acta Biochim Pol. 2003;50(1):231-8 [12673364.001]
  • [Cites] Lab Invest. 2003 Sep;83(9):1311-20 [13679439.001]
  • [Cites] Anticancer Res. 2004 Jan-Feb;24(1):155-9 [15015591.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Sep;153(2):127-32 [15350302.001]
  • [Cites] Mod Pathol. 2004 Nov;17(11):1328-37 [15154013.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 May;83(9):2934-8 [3458254.001]
  • [Cites] Cancer Genet Cytogenet. 1986 Aug;22(4):295-307 [3731046.001]
  • [Cites] Cancer Genet Cytogenet. 1987 Jan;24(1):63-73 [3791173.001]
  • [Cites] Histochemistry. 1988;89(4):307-16 [3410743.001]
  • [Cites] Cancer. 1990 Aug 1;66(3):491-7 [2364362.001]
  • [Cites] Virchows Arch. 1995;426(5):447-55 [7633655.001]
  • [Cites] Int J Cancer. 1996 May 29;66(5):594-9 [8647618.001]
  • [Cites] Cancer. 1995 Sep 1;76(5):720-6 [8625172.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7081-4 [8692948.001]
  • [Cites] Am J Pathol. 1996 Nov;149(5):1575-84 [8909247.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Dec;92(2):122-9 [8976368.001]
  • [Cites] Nihon Ika Daigaku Zasshi. 1997 Feb;64(1):22-9 [9119949.001]
  • [Cites] Oncology. 1997 Mar-Apr;54(2):166-70 [9075790.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Apr 1;102(1):88-90 [9530349.001]
  • [Cites] Nature. 1998 Dec 17;396(6712):643-9 [9872311.001]
  • [Cites] Am J Phys Anthropol. 1999 Jun;109(2):175-80 [10378456.001]
  • [Cites] J Int Med Res. 1999 Mar-Apr;27(2):85-9 [10446695.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2005 Apr;40(4):467-70 [15795596.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jun 10;331(3):694-700 [15865924.001]
  • [Cites] Br J Cancer. 2005 May 9;92(9):1759-66 [15827559.001]
  • [Cites] Anticancer Res. 2005 Nov-Dec;25(6B):4069-74 [16309200.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Aug;169(1):45-9 [16875936.001]
  • [Cites] Anticancer Res. 2006 Jul-Aug;26(4B):2909-14 [16886612.001]
  • [Cites] World J Gastroenterol. 2006 Oct 14;12(38):6207-11 [17036397.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3139-46 [10955795.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Aug;121(1):38-43 [10958939.001]
  • [Cites] Clin Exp Med. 2006 Oct;6(3):129-33 [17061062.001]
  • [Cites] Cancer Biol Ther. 2006 Sep;5(9):1154-60 [16855375.001]
  • [Cites] Arq Gastroenterol. 2006 Jul-Sep;43(3):247-51 [17160244.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2008 Jan;16(1):13-8 [18091326.001]
  • [Cites] Cancer Lett. 2008 Aug 8;266(2):99-115 [18381231.001]
  • [Cites] Lab Invest. 2000 Oct;80(10):1501-8 [11045566.001]
  • (PMID = 19619279.001).
  • [ISSN] 1471-230X
  • [Journal-full-title] BMC gastroenterology
  • [ISO-abbreviation] BMC Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ PMC2716360
  •  go-up   go-down


69. Bendrik C, Robertson J, Gauldie J, Dabrosin C: Gene transfer of matrix metalloproteinase-9 induces tumor regression of breast cancer in vivo. Cancer Res; 2008 May 1;68(9):3405-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene transfer of matrix metalloproteinase-9 induces tumor regression of breast cancer in vivo.
  • Here, adenovirus vectors carrying the human genes for MMP-9, TIMP-1, or empty controls were injected intratumorally in breast cancers established in mice supplemented with estradiol and treated with tamoxifen.
  • Microdialysis was used to quantify MMP activity and sampling of endostatin and vascular endothelial growth factor (VEGF) in situ.
  • Gene transfer of TIMP-1 had no effects on tumor progression and counteracted the therapeutic effect of tamoxifen in our breast cancer model.
  • This is the first report showing that overexpression of MMP-9 results in increased generation of antiangiogenic fragments, decreased angiogenesis, and therapeutic effects of established breast cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / therapy. Breast Neoplasms / genetics. Breast Neoplasms / therapy. Matrix Metalloproteinase 9 / genetics

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18451168.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Endostatins; 0 / Tissue Inhibitor of Metalloproteinase-1; 0 / Vascular Endothelial Growth Factor A; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


70. Broekhuizen LN, Wijsman JH, Peterse JL, Rutgers EJ: The incidence and significance of micrometastases in lymph nodes of patients with ductal carcinoma in situ and T1a carcinoma of the breast. Eur J Surg Oncol; 2006 Jun;32(5):502-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The incidence and significance of micrometastases in lymph nodes of patients with ductal carcinoma in situ and T1a carcinoma of the breast.
  • AIM: To report the incidence and predictive value of positive axillary nodes in ductal carcinoma in situ (DCIS) and T1a carcinoma of the breast.
  • All consecutive patients with primary breast cancer that were treated between 1989 and 1998 and who had undergone axillary dissection were selected.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma / secondary. Carcinoma in Situ / pathology. Carcinoma, Ductal, Breast / secondary. Lymphatic Metastasis / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Adult. Aged. Aged, 80 and over. Axilla. Carcinoma, Lobular / pathology. Carcinoma, Lobular / secondary. Female. Follow-Up Studies. Humans. Immunohistochemistry. Lymph Node Excision. Lymph Nodes / pathology. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Neoplastic Cells, Circulating / pathology. Retrospective Studies. Sentinel Lymph Node Biopsy. Survival Rate

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16569492.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


71. Chung AC, Zhou S, Liao L, Tien JC, Greenberg NM, Xu J: Genetic ablation of the amplified-in-breast cancer 1 inhibits spontaneous prostate cancer progression in mice. Cancer Res; 2007 Jun 15;67(12):5965-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic ablation of the amplified-in-breast cancer 1 inhibits spontaneous prostate cancer progression in mice.
  • Although the amplified-in-breast cancer 1 (AIB1; SRC-3, ACTR, or NCoA3) was defined as a coactivator for androgen receptor (AR) by in vitro studies, its role in AR-mediated prostate development and prostate cancer remained unexplored.
  • Surprisingly, when prostate tumorigenesis was induced by the SV40 transgene in transgenic adenocarcinoma of the mouse prostate (TRAMP) mice, AIB1 expression was observed in certain epithelial cells of the prostate intraepithelial neoplasia (PIN) and well-differentiated carcinoma and in almost all cells of the poorly differentiated carcinoma.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Sci (Lond). 2005 Apr;108(4):293-308 [15603554.001]
  • [Cites] Clin Cancer Res. 2005 Mar 15;11(6):2111-22 [15788656.001]
  • [Cites] J Biol Chem. 2005 Jul 1;280(26):25134-45 [15802273.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7976-83 [16140970.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7993-8002 [16140972.001]
  • [Cites] J Clin Oncol. 2005 Nov 10;23(32):8146-51 [16278465.001]
  • [Cites] Acta Pharmacol Sin. 2006 Apr;27(4):387-94 [16539836.001]
  • [Cites] Mol Cell Biol. 2006 May;26(10):3810-23 [16648476.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 7;103(45):16716-21 [17065319.001]
  • [Cites] Mol Cell Biol. 2004 Jun;24(12):5157-71 [15169882.001]
  • [Cites] J Biol Chem. 2004 Jul 23;279(30):31105-12 [15145939.001]
  • [Cites] Prostate. 2004 Oct 1;61(2):142-52 [15305337.001]
  • [Cites] Cancer Cell. 2004 Sep;6(3):263-74 [15380517.001]
  • [Cites] Biol Reprod. 1986 Jun;34(5):961-71 [3730488.001]
  • [Cites] Biol Reprod. 1986 Jun;34(5):973-83 [3730489.001]
  • [Cites] Cancer Res. 1996 Sep 15;56(18):4096-102 [8797572.001]
  • [Cites] Nature. 1997 Jun 12;387(6634):677-84 [9192892.001]
  • [Cites] Science. 1997 Aug 15;277(5328):965-8 [9252329.001]
  • [Cites] Clin Cancer Res. 1998 Dec;4(12):2925-9 [9865902.001]
  • [Cites] Am J Pathol. 1999 Feb;154(2):525-36 [10027410.001]
  • [Cites] Urology. 1999 Apr;53(4):707-13 [10197845.001]
  • [Cites] J Steroid Biochem Mol Biol. 1999 Apr-Jun;69(1-6):3-12 [10418975.001]
  • [Cites] Clin Cancer Res. 2004 Nov 15;10(22):7727-37 [15570007.001]
  • [Cites] Clin Sci (Lond). 2005 Jan;108(1):1-11 [15384949.001]
  • [Cites] Mol Endocrinol. 2006 Dec;20(12):3105-19 [16916939.001]
  • [Cites] Mol Endocrinol. 1999 Nov;13(11):1924-33 [10551785.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6379-84 [10823921.001]
  • [Cites] Int J Cancer. 2000 May 20;89(3):217-23 [10861496.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3650-4 [10910081.001]
  • [Cites] FEBS Lett. 2000 Nov 24;485(2-3):195-9 [11094166.001]
  • [Cites] Horm Metab Res. 2001 Mar;33(3):121-6 [11355743.001]
  • [Cites] Breast Cancer Res Treat. 2001 Jul;68(1):21-8 [11678305.001]
  • [Cites] Br J Cancer. 2001 Dec 14;85(12):1928-36 [11747336.001]
  • [Cites] Differentiation. 2001 Oct;68(4-5):270-9 [11776479.001]
  • [Cites] Cell. 2002 Feb 22;108(4):465-74 [11909518.001]
  • [Cites] Mol Cell Biol. 2002 May;22(10):3549-61 [11971985.001]
  • [Cites] Circulation. 2002 Jun 4;105(22):2653-9 [12045172.001]
  • [Cites] Cancer. 2002 Dec 1;95(11):2346-52 [12436441.001]
  • [Cites] J Neurosci. 2003 Jan 1;23(1):213-22 [12514218.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2226-30 [12589022.001]
  • [Cites] J Steroid Biochem Mol Biol. 2002 Dec;83(1-5):3-14 [12650696.001]
  • [Cites] N Engl J Med. 2003 Jul 24;349(4):366-81 [12878745.001]
  • [Cites] Mol Endocrinol. 2003 Sep;17(9):1681-92 [12805412.001]
  • [Cites] Mol Cell Biol. 2003 Nov;23(21):7742-55 [14560019.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1875-85 [14996752.001]
  • [Cites] J Biol Chem. 2004 Apr 9;279(15):14909-16 [14747462.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3334-43 [15126378.001]
  • [Cites] Prostate. 2003 May 15;55(3):219-37 [12692788.001]
  • (PMID = 17575167.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK58242; United States / NIDDK NIH HHS / DK / DK058242-05; United States / NCI NIH HHS / CA / CA119689-03; United States / NCI NIH HHS / CA / CA112403; United States / NCI NIH HHS / CA / R01 CA112403-02; United States / NCI NIH HHS / CA / CA112403-02; United States / NIDDK NIH HHS / DK / R01 DK058242-05; United States / NCI NIH HHS / CA / R01 CA119689-03; United States / NCI NIH HHS / CA / CA119689; United States / NCI NIH HHS / CA / R01 CA112403; United States / NIDDK NIH HHS / DK / R01 DK058242; United States / NCI NIH HHS / CA / R01 CA119689
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Androgen; 0 / Trans-Activators; EC 2.3.1.48 / Histone Acetyltransferases; EC 2.3.1.48 / Ncoa3 protein, mouse; EC 2.3.1.48 / Nuclear Receptor Coactivator 3
  • [Other-IDs] NLM/ NIHMS50339; NLM/ PMC2898573
  •  go-up   go-down


72. Kulka J, Tôkés AM, Kaposi-Novák P, Udvarhelyi N, Keller A, Schaff Z: Detection of HER-2/neu gene amplification in breast carcinomas using quantitative real-time PCR - a comparison with immunohistochemical and FISH results. Pathol Oncol Res; 2006;12(4):197-204
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of HER-2/neu gene amplification in breast carcinomas using quantitative real-time PCR - a comparison with immunohistochemical and FISH results.
  • The aim of our study was to evaluate the value of quantitative real-time-PCR (qPCR) in the determination of HER-2/neu amplification status of human breast carcinomas by comparing qPCR, FISH and immunohistochemistry results from the same samples.
  • A total of 210 breast carcinomas were examined.
  • In conclusion, a well calibrated HER-2/neu qPCR assay may serve as useful alternative to FISH in breast cancer patients.
  • [MeSH-major] Breast Neoplasms / genetics. Gene Amplification. Gene Expression Regulation, Neoplastic. Receptor, ErbB-2 / genetics. Receptor, ErbB-2 / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Female. Humans. Image Processing, Computer-Assisted / methods. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence / methods. Paraffin Embedding. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1988 Nov 10;319(19):1239-45 [2903446.001]
  • [Cites] J Clin Oncol. 2002 Jul 15;20(14):3095-105 [12118023.001]
  • [Cites] Am J Clin Pathol. 1999 Jul;112(1 Suppl 1):S53-67 [10396301.001]
  • [Cites] Oncogene. 2004 Jan 29;23(4):1010-3 [14647448.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1936-42 [8105035.001]
  • [Cites] Science. 1989 May 12;244(4905):707-12 [2470152.001]
  • [Cites] Int J Surg Pathol. 2004 Oct;12(4):311-8 [15494857.001]
  • [Cites] Mod Pathol. 1997 Aug;10(8):823-31 [9267826.001]
  • [Cites] Science. 1987 Jan 9;235(4785):177-82 [3798106.001]
  • [Cites] Am J Clin Pathol. 2000 Feb;113(2):251-8 [10664627.001]
  • [Cites] J Clin Pathol. 1992 Jan;45(1):16-20 [1346789.001]
  • [Cites] Magy Onkol. 2002;46(1):11-5 [12050677.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] Cancer Res. 1992 May 1;52(9):2597-602 [1348967.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):354-63 [11208826.001]
  • [Cites] J Pathol. 2001 Nov;195(4):422-8 [11745673.001]
  • [Cites] Am J Clin Pathol. 2001 Apr;115(4):504-11 [11293897.001]
  • [Cites] Int J Cancer. 1988 Dec 15;42(6):842-5 [2903851.001]
  • [Cites] Int J Cancer. 1998 May 18;76(4):459-63 [9590117.001]
  • [Cites] Int J Oncol. 2004 Oct;25(4):929-35 [15375542.001]
  • [Cites] Mod Pathol. 2000 Jan;13(1):37-45 [10658908.001]
  • [Cites] Int J Biol Markers. 2004 Jan-Mar;19(1):1-13 [15077921.001]
  • [Cites] Clin Cancer Res. 2005 Jun 15;11(12):4393-9 [15958623.001]
  • [Cites] Breast. 2003 Apr;12(2):92-8 [14659337.001]
  • [Cites] Neoplasia. 2003 Mar-Apr;5(2):128-34 [12659685.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):854-63 [14990641.001]
  • [Cites] BMC Clin Pathol. 2006 Jan 18;6:2 [16420697.001]
  • [Cites] Cancer. 2004 Feb 1;100(3):499-506 [14745865.001]
  • [Cites] Hum Pathol. 2003 Oct;34(10):1043-7 [14608539.001]
  • [Cites] Nature. 1986 Jan 16-22;319(6050):226-30 [3945311.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):599-605 [1548522.001]
  • [Cites] Int J Oncol. 1999 Apr;14(4):663-71 [10087312.001]
  • [Cites] J Mol Diagn. 2004 Feb;6(1):42-51 [14736826.001]
  • [Cites] Mod Pathol. 2000 Aug;13(8):866-73 [10955453.001]
  • [Cites] Int J Oncol. 2003 Nov;23(5):1285-92 [14532967.001]
  • [Cites] Arkh Patol. 2003 Jan-Feb;65(1):50-5 [12669615.001]
  • [Cites] Mayo Clin Proc. 2002 Feb;77(2):148-54 [11838648.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jan 16;313(3):709-15 [14697248.001]
  • [Cites] Mol Diagn. 2000 Sep;5(3):199-207 [11070154.001]
  • (PMID = 17189981.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


73. Mendes O, Kim HT, Stoica G: Expression of MMP2, MMP9 and MMP3 in breast cancer brain metastasis in a rat model. Clin Exp Metastasis; 2005;22(3):237-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of MMP2, MMP9 and MMP3 in breast cancer brain metastasis in a rat model.
  • In order to study the expression of MMP2, MMP3 and MMP9 in breast cancer brain metastasis, we used a syngeneic rat model of distant metastasis of ENU1564, a carcinogen-induced mammary adenocarcinoma cell line.
  • In situ zymography revealed gelatinase activity within the brain metastasis.
  • Furthermore, we were able to significantly decrease the development of breast cancer brain metastasis in animals by treatment with PD 166793, a selective synthetic MMP inhibitor.
  • Together our results suggest that MMP-2, -3 and -9 may be involved in the process of metastasis of breast cancer to the brain.
  • [MeSH-major] Adenocarcinoma / metabolism. Brain Neoplasms / metabolism. Breast Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Matrix Metalloproteinase 2 / genetics. Matrix Metalloproteinase 3 / genetics. Matrix Metalloproteinase 9 / genetics

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cancer Res Clin Oncol. 2005 Mar;131(3):191-8 [15592684.001]
  • [Cites] Eur J Neurosci. 2002 Jan;15(1):19-32 [11860503.001]
  • [Cites] Bioessays. 1992 Mar;14(3):185-94 [1586372.001]
  • [Cites] J Mol Cell Cardiol. 2003 May;35(5):539-48 [12738235.001]
  • [Cites] Breast Cancer Res Treat. 2001 Jan;65(1):55-61 [11245340.001]
  • [Cites] J Surg Res. 2003 Apr;110(2):383-92 [12788669.001]
  • [Cites] Acta Neurochir (Wien). 2003 Sep;145(9):825-38 [14505115.001]
  • [Cites] Genes Dev. 1999 Jan 1;13(1):35-48 [9887098.001]
  • [Cites] Cell. 2003 Jun 27;113(7):821-3 [12837240.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1320-6 [11245428.001]
  • [Cites] Breast Cancer Res Treat. 2000 Sep;63(2):105-15 [11097087.001]
  • [Cites] Clin Exp Metastasis. 2000;18(2):171-8 [11235993.001]
  • [Cites] J Orthop Sci. 2000;5(1):75-81 [10664443.001]
  • [Cites] Vet Pathol. 2003 May;40(3):227-36 [12724562.001]
  • [Cites] Clin Exp Metastasis. 1995 Mar;13(2):67-88 [7882617.001]
  • [Cites] Virchows Arch. 1999 Dec;435(6):566-73 [10628798.001]
  • [Cites] Circulation. 2002 Apr 23;105(16):1983-8 [11997287.001]
  • [Cites] Cancer Res. 2004 Jan 15;64(2):652-8 [14744781.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6758-62 [14583471.001]
  • [Cites] J Neurosci. 2003 May 15;23(10):4034-43 [12764090.001]
  • [Cites] Br J Cancer. 2003 Apr 22;88(8):1318-26 [12698202.001]
  • [Cites] Oncogene. 1997 Jun 12;14(23):2767-74 [9190892.001]
  • [Cites] Glia. 2003 Sep;43(3):254-64 [12898704.001]
  • [Cites] Clin Exp Metastasis. 2003;20(5):407-12 [14524529.001]
  • [Cites] Eur J Cancer. 2003 Jul;39(11):1632-41 [12855272.001]
  • [Cites] Int J Oncol. 2002 Jul;21(1):25-30 [12063545.001]
  • [Cites] Brain Res. 2001 Mar 2;893(1-2):104-12 [11222998.001]
  • [Cites] J Pathol. 1999 Oct;189(2):161-8 [10547569.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 1998 Apr;3(2):177-89 [10819526.001]
  • [Cites] Annu Rev Cell Biol. 1993;9:541-73 [8280471.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):1057-63 [14871985.001]
  • [Cites] Tumour Biol. 2003 Sep-Oct;24(5):258-70 [15001838.001]
  • [Cites] J Med Chem. 2000 Jan 27;43(2):156-66 [10649971.001]
  • [Cites] J Histochem Cytochem. 1999 Dec;47(12):1575-80 [10567441.001]
  • [Cites] Am J Pathol. 1996 Jul;149(1):273-82 [8686751.001]
  • [Cites] Br J Cancer. 2000 Dec;83(11):1538-43 [11076665.001]
  • [Cites] FEBS Lett. 2003 Oct 23;553(3):457-63 [14572669.001]
  • [Cites] Cancer Lett. 2004 Oct 28;214(2):205-13 [15363547.001]
  • [Cites] Anticancer Res. 1999 Sep-Oct;19(5B):4257-64 [10628384.001]
  • [Cites] Clin Exp Metastasis. 1994 Jul;12(4):283-95 [8039303.001]
  • [Cites] Endocrinology. 2000 Oct;141(10):3764-73 [11014232.001]
  • [Cites] Brain Res Mol Brain Res. 2002 Apr 30;100(1-2):103-17 [12008026.001]
  • [Cites] Lab Invest. 1997 Oct;77(4):357-68 [9354770.001]
  • [Cites] Melanoma Res. 1996 Oct;6(5):363-71 [8908596.001]
  • [Cites] Breast Cancer. 2002;9(1):26-32 [12196718.001]
  • [Cites] Breast Cancer Res. 2000;2(4):252-7 [11250717.001]
  • [Cites] Pathol Int. 2002 Apr;52(4):255-64 [12031080.001]
  • [Cites] Br J Cancer. 2004 Apr 5;90(7):1414-21 [15054465.001]
  • (PMID = 16158251.001).
  • [ISSN] 0262-0898
  • [Journal-full-title] Clinical & experimental metastasis
  • [ISO-abbreviation] Clin. Exp. Metastasis
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R01-NS046214-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / (R)-2-(4'-bromo-biphenyl-4-sulfonyl-amino)-3-methyl-butyric acid; 0 / Hydroxamic Acids; 0 / Oligopeptides; 0 / RNA, Messenger; EC 3.4.24.17 / Matrix Metalloproteinase 3; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


74. Marchesoni D, Driul L, Mozzanega B, Nardelli GB, Parenti A: Intraepithelial G3 adenocarcinoma of the endometrium after tamoxifen treatment. Arch Gynecol Obstet; 2005 Jan;271(1):62-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraepithelial G3 adenocarcinoma of the endometrium after tamoxifen treatment.
  • A polypoid endometrium completely filled the uterine cavity and was carefully removed by curettage; histology showed a highly undifferentiated neoplasia with a component of serous adenocarcinoma, which was likely to originate from endometrial polyps.
  • [MeSH-major] Adenocarcinoma / chemically induced. Anticarcinogenic Agents / adverse effects. Antineoplastic Agents, Hormonal / adverse effects. Carcinoma in Situ / chemically induced. Endometrial Neoplasms / chemically induced. Tamoxifen / adverse effects
  • [MeSH-minor] Breast Neoplasms / drug therapy. Breast Neoplasms / surgery. Carcinoma, Ductal / drug therapy. Carcinoma, Ductal / surgery. Chemotherapy, Adjuvant. Dilatation and Curettage. Endometrium / drug effects. Endometrium / pathology. Female. Humans. Hysteroscopy. Mastectomy, Radical. Middle Aged

  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15290168.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


75. Farshid G, Pieterse S, King JM, Robinson J: Mucocele-like lesions of the breast: a benign cause for indeterminate or suspicious mammographic microcalcifications. Breast J; 2005 Jan-Feb;11(1):15-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucocele-like lesions of the breast: a benign cause for indeterminate or suspicious mammographic microcalcifications.
  • Most earlier reports of mucocele-like lesions (MLL) of the breast have dealt with symptomatic cases in premenopausal women or lesions found incidentally in breast biopsies performed for other reasons.
  • The diagnosis of this lesion has special challenges in the setting of mammographic screening for breast cancer because the imaging characteristics of MLL may mimic those of ductal carcinoma in situ (DCIS), while mucinous carcinoma enters the differential diagnosis on cytologic grounds.
  • Cases with MLL as the final histologic diagnosis in our database during January 1992-June 2000 are included.
  • Correlating the cytomorphology of mucinous lesions of the breast with their mammographic appearance may permit more precise preoperative diagnosis.
  • [MeSH-major] Adenocarcinoma, Mucinous / epidemiology. Adenocarcinoma, Mucinous / radiography. Breast Neoplasms / epidemiology. Breast Neoplasms / radiography

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15647073.001).
  • [ISSN] 1075-122X
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Fröhlich C, Albrechtsen R, Dyrskjøt L, Rudkjaer L, Ørntoft TF, Wewer UM: Molecular profiling of ADAM12 in human bladder cancer. Clin Cancer Res; 2006 Dec 15;12(24):7359-68
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: We have previously found ADAM12, a disintegrin and metalloprotease, to be an interesting biomarker for breast cancer.
  • Gene expression in bladder cancer was validated using reverse transcription-PCR, quantitative PCR, and in situ hybridization.
  • Reverse transcription-PCR, quantitative PCR, and in situ hybridization validated the gene expression results.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adenocarcinoma / urine. Adult. Aged. Aged, 80 and over. Amyloid Precursor Protein Secretases / metabolism. Animals. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Carcinoma, Squamous Cell / urine. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Mammary Neoplasms, Experimental / metabolism. Mammary Neoplasms, Experimental / pathology. Mice. Middle Aged. Mucous Membrane / metabolism. Neoplasm Recurrence, Local / urine. Neoplasm Staging

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17189408.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membrane Proteins; EC 3.4.- / Amyloid Precursor Protein Secretases; EC 3.4.24.- / ADAM 12 protein; EC 3.4.24.- / ADAM Proteins; EC 3.4.24.- / ADAM8 protein, human; EC 3.4.24.81 / ADAM10 protein, human
  •  go-up   go-down


77. Letessier A, Ginestier C, Charafe-Jauffret E, Cervera N, Adélaïde J, Gelsi-Boyer V, Ahomadegbe JC, Benard J, Jacquemier J, Birnbaum D, Chaffanet M: ETV6 gene rearrangements in invasive breast carcinoma. Genes Chromosomes Cancer; 2005 Sep;44(1):103-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ETV6 gene rearrangements in invasive breast carcinoma.
  • We looked for ETV6 rearrangements in invasive breast cancer using fluorescence in situ hybridization (FISH) of BAC probes on sections of tissue microarrays containing 632 tumor samples.
  • [MeSH-major] Breast Neoplasms / genetics. DNA-Binding Proteins / genetics. Nuclear Proteins / genetics. Repressor Proteins / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adult. Aged. Aged, 80 and over. Artificial Gene Fusion. Centromere / genetics. Chromosome Mapping. Female. Gene Rearrangement. Humans. In Situ Hybridization, Fluorescence. Middle Aged. Neoplasm Invasiveness. Proto-Oncogene Proteins c-ets. Telomere / genetics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15887243.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / ETS translocation variant 6 protein; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins c-ets; 0 / Repressor Proteins
  •  go-up   go-down


78. Emanuel PO, de Vinck D, Waldorf HA, Phelps RG: Recurrent endocrine mucin-producing sweat gland carcinoma. Ann Diagn Pathol; 2007 Dec;11(6):448-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Morphologically and immunohistochemically, it is analogous to endocrine ductal carcinoma in situ of the breast and mammary solid papillary carcinoma; also, like the analogous breast lesion, there is an often associated invasive mucinous carcinoma with neuroendocrine differentiation.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Eyelid Neoplasms / pathology. Mucins / biosynthesis. Neoplasm Recurrence, Local / pathology. Sweat Gland Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18022131.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mucins
  •  go-up   go-down


79. Akli S, Van Pelt CS, Bui T, Multani AS, Chang S, Johnson D, Tucker S, Keyomarsi K: Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway. Cancer Res; 2007 Aug 1;67(15):7212-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When overexpressed in breast cancer cells, these forms of cyclin E induce genomic instability, resistance to inhibition by p21 and p27, and resistance to antiestrogen therapy.
  • Additionally, the LMW forms of cyclin E strongly correlate with decreased survival in patients with breast cancer.
  • However, the oncologic role of the LMW forms of cyclin E in breast cancer tumorigenesis is yet to be determined.
  • [MeSH-major] Adenocarcinoma / secondary. Cyclin E / genetics. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Gene Expression Regulation, Neoplastic / physiology. Lung Neoplasms / secondary. Mammary Neoplasms, Experimental / pathology. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Animals. Apoptosis. Blotting, Western. Female. Gene Silencing. Humans. Immunoenzyme Techniques. In Situ Nick-End Labeling. Loss of Heterozygosity. Mice. Mice, Knockout. Mice, Transgenic. Mutation. Polymerase Chain Reaction. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17671189.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5P50CA116199; United States / NCI NIH HHS / CA / 5R01CA087548-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cdkn2a protein, mouse; 0 / Cyclin E; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


80. Ghule PN, Dominski Z, Lian JB, Stein JL, van Wijnen AJ, Stein GS: The subnuclear organization of histone gene regulatory proteins and 3' end processing factors of normal somatic and embryonic stem cells is compromised in selected human cancer cell types. J Cell Physiol; 2009 Jul;220(1):129-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using in situ immuno-fluorescence microscopy and fluorescence in situ hybridization (FISH), we show that this subnuclear organization is compromised in some cancer cell lines.
  • More importantly, the in situ co-localization of p220(NPAT) and Lsm10 is disrupted in HeLa S3 cervical carcinoma cells and MCF7 breast adenocarcinoma cells, with most Lsm10 residing in Cajal Bodies.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10334-42 [17974976.001]
  • [Cites] J Cell Biochem. 2008 Aug 15;104(6):2016-26 [18615590.001]
  • [Cites] Cell Cycle. 2008 Aug;7(15):2357-67 [18677100.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):16964-9 [18957539.001]
  • [Cites] Genes Dev. 2000 Sep 15;14(18):2283-97 [10995386.001]
  • [Cites] Genes Dev. 2000 Sep 15;14(18):2298-313 [10995387.001]
  • [Cites] Annu Rev Cell Dev Biol. 2000;16:273-300 [11031238.001]
  • [Cites] EMBO J. 2001 Oct 1;20(19):5470-9 [11574479.001]
  • [Cites] Mol Cell Biol. 2002 Mar;22(5):1424-37 [11839809.001]
  • [Cites] J Cell Biol. 2002 Oct 14;159(1):17-21 [12379800.001]
  • [Cites] Mol Cell Biol. 2003 May;23(10):3669-80 [12724424.001]
  • [Cites] Genes Dev. 2003 Sep 15;17(18):2321-33 [12975319.001]
  • [Cites] Mol Cell. 2003 Aug;12(2):295-305 [14536070.001]
  • [Cites] Mol Cell Biol. 2003 Nov;23(22):8110-23 [14585971.001]
  • [Cites] Mol Cell Biol. 2003 Dec;23(23):8586-600 [14612403.001]
  • [Cites] Proc Natl Acad Sci U S A. 1974 Apr;71(4):1286-90 [4524638.001]
  • [Cites] Nucleic Acids Res. 1983 Apr 25;11(8):2391-410 [6304651.001]
  • [Cites] Mol Cell Biol. 1983 Nov;3(11):1920-9 [6656760.001]
  • [Cites] Biochemistry. 1987 Sep 22;26(19):6178-87 [3689769.001]
  • [Cites] Science. 1989 Nov 3;246(4930):603-8 [2683075.001]
  • [Cites] J Exp Med. 1991 Jun 1;173(6):1407-19 [2033369.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 20;92(13):5915-9 [7597053.001]
  • [Cites] Cell Biol Int. 1996 Jan;20(1):41-9 [8936406.001]
  • [Cites] Genes Dev. 1996 Dec 1;10(23):3028-40 [8957003.001]
  • [Cites] Genes Dev. 1998 Feb 15;12(4):456-61 [9472014.001]
  • [Cites] Gene. 2004 Nov 10;342(1):35-40 [15527963.001]
  • [Cites] Mol Cell Biol. 2005 Jul;25(14):6140-53 [15988025.001]
  • [Cites] J Biol Chem. 2005 Nov 11;280(45):37400-7 [16131487.001]
  • [Cites] J Cell Biol. 2006 Mar 13;172(6):875-84 [16533947.001]
  • [Cites] J Cell Physiol. 2006 Dec;209(3):883-93 [16972248.001]
  • [Cites] J Cell Physiol. 2007 Feb;210(2):517-26 [17096384.001]
  • [Cites] Biochemistry. 2006 Dec 26;45(51):15915-20 [17176114.001]
  • [Cites] Nat Rev Cancer. 2007 Jun;7(6):454-63 [17522714.001]
  • [Cites] Gene. 2007 Jul 15;396(2):373-90 [17531405.001]
  • [Cites] Mol Biol Cell. 2007 Jul;18(7):2491-502 [17442888.001]
  • [Cites] J Cell Physiol. 2007 Oct;213(1):9-17 [17520687.001]
  • (PMID = 19277982.001).
  • [ISSN] 1097-4652
  • [Journal-full-title] Journal of cellular physiology
  • [ISO-abbreviation] J. Cell. Physiol.
  • [Language] ENG
  • [Grant] United States / NIDCR NIH HHS / DE / R37 DE012528; United States / NIGMS NIH HHS / GM / R01 GM058921-02; United States / NCI NIH HHS / CA / P01 CA082834-10; United States / NIGMS NIH HHS / GM / GM058921-02; United States / NCI NIH HHS / CA / CA082834-10; United States / NIGMS NIH HHS / GM / R01 GM032010-23; United States / NIGMS NIH HHS / GM / R01 GM058921; United States / NIGMS NIH HHS / GM / GM032010-23; United States / NCI NIH HHS / CA / P01 CA082834; United States / NIGMS NIH HHS / GM / R01 GM032010
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Histones; 0 / LSM10 protein, human; 0 / NPAT protein, human; 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / Ribonucleoproteins, Small Nuclear
  • [Other-IDs] NLM/ NIHMS301281; NLM/ PMC3167205
  •  go-up   go-down


81. van Deurzen CH, Borgstein PJ, van Diest PJ: In-transit lymph node metastases in breast cancer: a possible source of local recurrence after Sentinel Node procedure. J Clin Pathol; 2008 Dec;61(12):1314-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In-transit lymph node metastases in breast cancer: a possible source of local recurrence after Sentinel Node procedure.
  • To which extent this also occurs in patients with breast cancer has not been studied yet.
  • The aim of this study was therefore to explore the occurrence of in-transit lymph node metastases in patients with breast cancer.
  • METHODS: Afferent lymph vessels to the SN identified by blue dye were removed from 17 patients with breast cancer during a regular SN procedure.
  • One of these lymph nodes showed a breast cancer macrometastasis, to be regarded as an in-transit metastasis.
  • This metastasis would normally have been left in situ.
  • CONCLUSIONS: In-transit lymph nodes associated with the afferent SN lymph vessels seem to occur in a significant proportion of patients with breast cancer.
  • These lymph nodes may contain metastases, which are a potential source of local recurrence when left in situ.
  • [MeSH-major] Breast Neoplasms / pathology. Lymphatic Metastasis. Neoplasm Recurrence, Local / etiology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Female. Humans. Lymph Node Excision. Sentinel Lymph Node Biopsy

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Pathol. 2008 Dec;61(12):1233-5 [18829625.001]
  • (PMID = 18794198.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


82. Persons DL, Tubbs RR, Cooley LD, Dewald GW, Dowling PK, Du E, Mascarello JT, Rao KW, Wilson KS, Wolff DJ, Habegger-Vance G: HER-2 fluorescence in situ hybridization: results from the survey program of the College of American Pathologists. Arch Pathol Lab Med; 2006 Mar;130(3):325-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HER-2 fluorescence in situ hybridization: results from the survey program of the College of American Pathologists.
  • CONTEXT: Fluorescence in situ hybridization (FISH) is a common method used to determine HER-2 status in breast cancer.
  • DESIGN: During the past 5 years, unstained sections from 9 invasive breast carcinomas were used for HER-2 FISH proficiency testing, allowing for comparison of FISH results among a large number of laboratories.
  • Reproducibility of test results among laboratories was excellent for breast tumors with low copy number (no HER-2 amplification) and for breast tumors with high copy number (HER-2 amplification).
  • [MeSH-major] Adenocarcinoma / genetics. Breast Neoplasms / genetics. Cytogenetic Analysis / standards. In Situ Hybridization / standards. Receptor, ErbB-2 / genetics. Societies, Medical

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16519559.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


83. Shen SG, Zhang D, Hu HT, Li JH, Wang Z, Ma QY: Effects of alpha-adrenoreceptor antagonists on apoptosis and proliferation of pancreatic cancer cells in vitro. World J Gastroenterol; 2008 Apr 21;14(15):2358-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We cultured the human ductal pancreatic adenocarcinoma cell lines PC-2 and PC-3 and analyzed the mRNA expression of alpha1- and alpha2-adrenergic receptors by reverse transcription polymerase chain reaction (RT-PCR).
  • [MeSH-minor] Adrenergic alpha-1 Receptor Antagonists. Cell Line, Tumor. DNA Replication / drug effects. Dose-Response Relationship, Drug. Flow Cytometry. Gene Expression Regulation, Neoplastic. Humans. In Situ Nick-End Labeling. Piperazines / pharmacology. RNA, Messenger / metabolism. Receptors, Adrenergic, alpha-1 / metabolism. Receptors, Adrenergic, alpha-2 / genetics. Receptors, Adrenergic, alpha-2 / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 2006 Jul;58(1):50-61 [16292538.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2006 Apr;20(2):197-209 [16549324.001]
  • [Cites] Ann Oncol. 2007 Jun;18 Suppl 7:vii1-vii10 [17600091.001]
  • [Cites] Nat Clin Pract Oncol. 2007 Sep;4(9):526-35 [17728711.001]
  • [Cites] Pancreatology. 2007;7(5-6):459-69 [17912010.001]
  • [Cites] Circulation. 2000 Feb 15;101(6):689-94 [10673263.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4550-5 [10969806.001]
  • [Cites] Carcinogenesis. 2001 Mar;22(3):473-9 [11238189.001]
  • [Cites] Pharmacol Res. 2001 Sep;44(3):195-208 [11529686.001]
  • [Cites] World J Gastroenterol. 2001 Aug;7(4):482-9 [11819814.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):455-63 [12189387.001]
  • [Cites] Herz. 2002 Nov;27(7):683-90 [12439640.001]
  • [Cites] J Urol. 2003 Apr;169(4):1520-5 [12629407.001]
  • [Cites] Biochem Pharmacol. 2003 May 1;65(9):1489-94 [12732361.001]
  • [Cites] Vet Res Commun. 2003 Sep;27 Suppl 1:415-8 [14535443.001]
  • [Cites] Am J Cardiol. 1987 May 29;59(14):18G-28G [2884849.001]
  • [Cites] J Biol Chem. 1993 Oct 25;268(30):22235-8 [8226727.001]
  • [Cites] Pharmacol Res. 1996 Apr-May;33(4-5):255-60 [8938018.001]
  • [Cites] J Auton Pharmacol. 1997 Dec;17(6):331-43 [9610428.001]
  • [Cites] Eur J Pharmacol. 1998 Nov 13;361(1):1-15 [9851536.001]
  • [Cites] Eur Urol. 1999;36 Suppl 1:80-8 [10393479.001]
  • [Cites] Breast Cancer Res Treat. 1999 May;55(1):41-9 [10472778.001]
  • [Cites] Cancer Res. 1999 Sep 15;59(18):4510-5 [10493497.001]
  • [Cites] Pancreas. 2005 Nov;31(4):301-16 [16258363.001]
  • [Cites] Crit Rev Oncol Hematol. 2006 Jun;58(3):231-41 [16725343.001]
  • (PMID = 18416462.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adrenergic alpha-1 Receptor Antagonists; 0 / Adrenergic alpha-2 Receptor Antagonists; 0 / Adrenergic alpha-Antagonists; 0 / Antineoplastic Agents; 0 / Piperazines; 0 / RNA, Messenger; 0 / Receptors, Adrenergic, alpha-1; 0 / Receptors, Adrenergic, alpha-2; 2Y49VWD90Q / Yohimbine; A78GF17HJS / urapidil
  • [Other-IDs] NLM/ PMC2705090
  •  go-up   go-down


84. Graham AD, Faratian D, Rae F, Thomas JS: Tissue microarray technology in the routine assessment of HER-2 status in invasive breast cancer: a prospective study of the use of immunohistochemistry and fluorescence in situ hybridization. Histopathology; 2008 Jun;52(7):847-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue microarray technology in the routine assessment of HER-2 status in invasive breast cancer: a prospective study of the use of immunohistochemistry and fluorescence in situ hybridization.
  • AIMS: To compare tissue microarray (TMA) and whole-section (WS) techniques in the routine assessment of HER-2 status in invasive breast cancer by immunohistochemistry and fluorescence in situ hybridization (FISH).
  • METHODS AND RESULTS: HER-2 status was assessed prospectively in 106 consecutive cases of excised high-grade and/or node-positive breast carcinoma using both WS- and TMA-based techniques.
  • CONCLUSIONS: TMA technology is a robust method of assessing HER-2 status in invasive breast cancer.
  • [MeSH-major] Breast Neoplasms / metabolism. Immunohistochemistry. In Situ Hybridization, Fluorescence. Receptor, ErbB-2 / metabolism. Tissue Array Analysis / methods
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Lobular / genetics. Carcinoma, Lobular / metabolism. DNA, Neoplasm / analysis. Female. Humans. Prospective Studies. Reproducibility of Results


85. Atkin GK, Daley FM, Bourne S, Glynne-Jones R, Northover JM, Wilson GD: The impact of surgically induced ischaemia on protein levels in patients undergoing rectal cancer surgery. Br J Cancer; 2006 Oct 9;95(7):928-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Colorectal cancer surgery significantly impacts on intratumoral gene expression, suggesting archival specimens may not accurately reflect in situ marker levels.
  • [MeSH-major] Adenocarcinoma / surgery. Biomarkers, Tumor / metabolism. Gene Expression. Ischemia / metabolism. Rectal Neoplasms / surgery

  • Genetic Alliance. consumer health - Rectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2006 Jan 16;94(1):121-7 [16404365.001]
  • [Cites] Hum Pathol. 2005 Dec;36(12):1302-8 [16311124.001]
  • [Cites] Am J Med Sci. 1993 Jul;306(1):37-41 [8328508.001]
  • [Cites] Pharm World Sci. 1994 Apr 15;16(2):84-103 [7518280.001]
  • [Cites] Nucleic Acids Res. 1995 Nov 25;23(22):4649-56 [8524656.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):1063-72 [10741735.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1378-84 [10778966.001]
  • [Cites] Eur J Cancer. 2000 Aug;36(13 Spec No):1649-60 [10959051.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):7075-83 [11156414.001]
  • [Cites] Oncol Rep. 2001 May-Jun;8(3):497-500 [11295069.001]
  • [Cites] J Surg Res. 2001 Aug;99(2):222-7 [11469890.001]
  • [Cites] J Natl Cancer Inst. 2001 Sep 5;93(17):1337-43 [11535709.001]
  • [Cites] Cancer Treat Rev. 2002 Feb;28(1):27-47 [12027413.001]
  • [Cites] Mol Cell Biol. 2003 Jan;23(1):359-69 [12482987.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):241-50 [12525515.001]
  • [Cites] Oncol Rep. 2003 Jul-Aug;10(4):867-9 [12792736.001]
  • [Cites] Anal Biochem. 2004 May 15;328(2):101-8 [15113684.001]
  • [Cites] Breast Cancer Res. 2004;6(4):R450-9 [15217513.001]
  • [Cites] Exp Mol Pathol. 2004 Dec;77(3):222-30 [15507240.001]
  • [Cites] Biochemistry. 1974 Jan 29;13(3):471-81 [4203910.001]
  • [Cites] J Biol Chem. 1987 Mar 25;262(9):4098-103 [3549724.001]
  • [Cites] Cancer Res. 1997 Feb 15;57(4):570-2 [9044826.001]
  • [Cites] Exp Physiol. 1997 Mar;82(2):361-8 [9129950.001]
  • [Cites] Clin Cancer Res. 1998 Oct;4(10):2371-6 [9796967.001]
  • [Cites] Histopathology. 1989 Dec;15(6):653-8 [2606461.001]
  • (PMID = 17016487.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.1.1.45 / Thymidylate Synthase
  • [Other-IDs] NLM/ PMC2360543
  •  go-up   go-down


86. Eusebi V, Millis RR: Epitheliosis, infiltrating epitheliosis, and radial scar. Semin Diagn Pathol; 2010 Feb;27(1):5-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The differential diagnosis from radial scar (RS) is discussed.
  • IE can be associated with either in situ or invasive carcinoma, whereas RS being more like a process of involution is very seldom involved by a carcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Diseases / pathology. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Cicatrix / pathology. Mammary Glands, Human / pathology
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Sclerosis / pathology. Terminology as Topic

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • MedlinePlus Health Information. consumer health - Scars.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20306826.001).
  • [ISSN] 0740-2570
  • [Journal-full-title] Seminars in diagnostic pathology
  • [ISO-abbreviation] Semin Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. McHugh JB, Visscher DW, Barnes EL: Update on selected salivary gland neoplasms. Arch Pathol Lab Med; 2009 Nov;133(11):1763-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Polymorphous low-grade adenocarcinoma can be a challenging diagnosis on biopsy specimens.
  • Evaluation of the tumor periphery and nuclear features should lead to the correct diagnosis in most cases.
  • Salivary duct carcinoma is an aggressive malignancy characterized by histologic resemblance to breast carcinoma, high-grade cytologic features, and expression of androgen receptor.
  • Benign and malignant myoepithelial neoplasms have a broad morphologic spectrum, and immunohistochemistry is important in reaching the correct diagnosis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenoma, Pleomorphic / diagnosis. Carcinoma in Situ / diagnosis. Carcinosarcoma / diagnosis. Salivary Gland Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19886710.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


88. Ding HY, Yang GZ: [Clinicopathological features of the mucocele-like lesions in the breast]. Zhonghua Bing Li Xue Za Zhi; 2008 Jan;37(1):31-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathological features of the mucocele-like lesions in the breast].
  • OBJECTIVE: To study the clinical and pathological features of mucocele-like lesions in the breast.
  • METHODS: Nine cases of mucocele-like lesions in the breast were reported for the morphological and immunohistochemical features, the differential diagnosis, and a literature review.
  • RESULTS: All nine cases were from female patients, aged 23 to 43 years (mean 34 years), clinically presented with palpable breast masses.
  • CONCLUSION: Mucocele-like lesions of the breast is a group of mostly benign disease, and the differential diagnosis should include mucinous carcinoma.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Diagnosis, Differential. Hyperplasia / pathology. Mucocele / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / pathology. Carcinoma in Situ / diagnosis. Female. Gene Expression Regulation, Neoplastic / physiology. Humans. Intestinal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18509982.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


89. Adélaïde J, Finetti P, Bekhouche I, Repellini L, Geneix J, Sircoulomb F, Charafe-Jauffret E, Cervera N, Desplans J, Parzy D, Schoenmakers E, Viens P, Jacquemier J, Birnbaum D, Bertucci F, Chaffanet M: Integrated profiling of basal and luminal breast cancers. Cancer Res; 2007 Dec 15;67(24):11565-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integrated profiling of basal and luminal breast cancers.
  • Basal and luminal are two molecular subtypes of breast cancer with opposite histoclinical features.
  • We report a combined, high-resolution analysis of genome copy number and gene expression in primary basal and luminal breast cancers.
  • We show that gain of 10p is a new alteration in basal breast cancer and that a subregion of the 8p12 amplification is specific of luminal tumors.
  • Second, we analyzed both aCGH and gene expression profiles for 42 basal and 32 luminal breast cancers.
  • The results support the existence of specific oncogenic pathways in basal and luminal breast cancers, involving several potential oncogenes and tumor suppressor genes (TSG).
  • In luminal breast cancers, 33 potential oncogenes were identified in 1q21-23, 8p12-q21, 11q13, and 16p12-13 and 61 candidate TSG in 16q12-13, 16q22-24, and 17p13.
  • [MeSH-major] Breast Neoplasms / genetics. Chromosomes, Human, Pair 8. Gene Expression Profiling
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Chromosome Mapping. DNA, Neoplasm / genetics. DNA, Neoplasm / isolation & purification. Female. Gene Amplification. Humans. In Situ Hybridization, Fluorescence. Nucleic Acid Hybridization. Oligonucleotide Array Sequence Analysis. RNA, Neoplasm / genetics. RNA, Neoplasm / isolation & purification


90. Kuuselo R, Simon R, Karhu R, Tennstedt P, Marx AH, Izbicki JR, Yekebas E, Sauter G, Kallioniemi A: 19q13 amplification is associated with high grade and stage in pancreatic cancer. Genes Chromosomes Cancer; 2010 Jun;49(6):569-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We used fluorescence in situ hybridization on tissue microarrays containing 357 primary pancreatic tumors, 151 metastases, and 24 local recurrences as well as 120 cancer cell lines from various tissues to establish the frequency of the 19q13 amplification and to find potential correlations to clinical parameters including patient survival.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc.
  • [Cites] Genes Chromosomes Cancer. 2009 Apr;48(4):289-309 [19105235.001]
  • [Cites] PLoS Genet. 2008 May;4(5):e1000081 [18535672.001]
  • [Cites] Mod Pathol. 2009 Apr;22(4):499-507 [19151661.001]
  • [Cites] Cancer Biol Ther. 2008 Nov;7(11):1793-802 [18836286.001]
  • [Cites] Am J Pathol. 2000 Sep;157(3):787-94 [10980118.001]
  • [Cites] Cancer Lett. 2001 Jun 26;167(2):115-23 [11369131.001]
  • [Cites] Cytometry. 2001 Oct 1;45(2):83-6 [11590619.001]
  • [Cites] Clin Cancer Res. 2002 Jun;8(6):1720-30 [12060609.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Dec;35(4):353-8 [12378529.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7157-61 [12499249.001]
  • [Cites] Breast Cancer Res Treat. 2003 Apr;78(3):337-45 [12755492.001]
  • [Cites] BMC Cancer. 2004 Feb 6;4:5 [15018632.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):9067-72 [15199222.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4428-33 [15231651.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Jul;84(14):5034-7 [3037531.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 May 15;89(10):4285-9 [1350088.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9267-71 [1409633.001]
  • [Cites] Int J Cancer. 1993 Sep 30;55(3):422-8 [8375927.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2156-60 [8134364.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7):1801-6 [8137295.001]
  • [Cites] Int J Cancer. 1995 Aug 22;64(4):280-5 [7657393.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Mar;87(1):55-62 [8646743.001]
  • [Cites] Clin Cancer Res. 1998 Oct;4(10):2383-90 [9796969.001]
  • [Cites] Am J Clin Pathol. 1999 Jul;112(1 Suppl 1):S11-8 [10396297.001]
  • [Cites] Neoplasia. 2004 Sep-Oct;6(5):432-9 [15548351.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8534-40 [15574759.001]
  • [Cites] Oncogene. 2005 Mar 3;24(10):1794-801 [15688027.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Sep;44(1):37-51 [15929091.001]
  • [Cites] Neoplasia. 2005 Jun;7(6):556-62 [16036106.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8235-42 [16322280.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4149-58 [16618736.001]
  • [Cites] Oncogene. 2006 Jun 1;25(23):3247-57 [16491129.001]
  • [Cites] Trends Genet. 2006 Aug;22(8):447-55 [16787682.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):1943-9 [17332321.001]
  • [Cites] Genes Chromosomes Cancer. 2009 Apr;48(4):330-9 [19145645.001]
  • (PMID = 20232484.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA109552-01A1; United States / NCI NIH HHS / CA / P01 CA109552; United States / NCI NIH HHS / CA / P01 CA109552-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS189142; NLM/ PMC2855495
  •  go-up   go-down


91. Zhang XL, Yang GZ, Ding HY: [Pathological study of radial sclerosing lesions]. Zhonghua Bing Li Xue Za Zhi; 2010 Jan;39(1):10-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the pathological diagnostic features and the differential diagnosis of radial sclerosing lesions of the breast.
  • METHODS: Morphological observation and immunohistochemistry were applied to forty-four cases of radial sclerosing lesions of the breast.
  • CONCLUSIONS: Radial sclerosing lesions of the breast possess characteristic histological features, and may be misdiagnosed as carcinoma.
  • The lesions should be differentiated from ductal carcinoma in situ, lobular neoplasia, tubular carcinoma and invasive ductal carcinoma.
  • [MeSH-major] Breast / pathology. Breast Diseases / pathology. Keratin-5 / metabolism. Sclerosis / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adolescent. Adult. Breast Neoplasms / pathology. Carcinoma in Situ / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Lobular / pathology. Diagnosis, Differential. Diagnostic Errors. Female. Humans. Hyperplasia. Keratin-14 / metabolism. Keratins / metabolism. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20388392.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CK-34 beta E12; 0 / Keratin-14; 0 / Keratin-5; 68238-35-7 / Keratins
  •  go-up   go-down


92. Aulmann S, Adler N, Rom J, Helmchen B, Schirmacher P, Sinn HP: c-myc amplifications in primary breast carcinomas and their local recurrences. J Clin Pathol; 2006 Apr;59(4):424-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] c-myc amplifications in primary breast carcinomas and their local recurrences.
  • OBJECTIVE: To evaluate the role of c-myc oncogene amplifications in the progression of invasive breast carcinomas.
  • METHODS: c-myc gene copy number was evaluated in a series of 49 primary breast carcinomas and the corresponding local recurrences using fluorescence in situ hybridisation.
  • CONCLUSIONS: While c-myc amplifications can be observed in early stage breast cancer, especially in younger patients, they often occur later in tumour development and appear to be associated with disease progression.
  • [MeSH-major] Breast Neoplasms / genetics. Carcinoma, Ductal, Breast / genetics. Carcinoma, Lobular / genetics. Gene Amplification. Genes, myc. Neoplasm Recurrence, Local / genetics
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / genetics. Adult. Aged. Aged, 80 and over. Female. Genes, p53. Humans. Immunohistochemistry / methods. In Situ Hybridization, Fluorescence. Lymphatic Metastasis. Middle Aged. Proportional Hazards Models. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 2002 Mar;22(6):1819-33 [11865060.001]
  • [Cites] Br J Cancer. 2003 Oct 20;89(8):1479-85 [14562020.001]
  • [Cites] Cancer. 2004 Jan 15;100(2):252-63 [14716758.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10(2):499-507 [14760071.001]
  • [Cites] Am J Clin Oncol. 2004 Apr;27(2):185-90 [15057159.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Sep;41(1):1-11 [15236312.001]
  • [Cites] Am J Pathol. 1991 Sep;139(3):495-501 [1887859.001]
  • [Cites] Hum Mol Genet. 1992 Nov;1(8):625-32 [1301171.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1993;422(4):319-26 [8389501.001]
  • [Cites] Methods Enzymol. 1995;254:334-59 [8531697.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Aug;19(4):267-72 [9258662.001]
  • [Cites] Oncogene. 1997 Oct 9;15(15):1787-95 [9362445.001]
  • [Cites] Oncogene. 1998 May 28;16(21):2755-66 [9652742.001]
  • [Cites] Eur J Cancer. 1998 Apr;34(5):646-53 [9713268.001]
  • [Cites] Cancer. 1999 Jan 15;85(2):437-46 [10023713.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8534-40 [15574759.001]
  • [Cites] Am J Surg. 2005 Feb;189(2):229-35 [15720997.001]
  • [Cites] Cancer. 2002 Jun 1;94(11):2813-20 [12115367.001]
  • [Cites] Clin Cancer Res. 1999 Dec;5(12):4140-5 [10632352.001]
  • [Cites] Oncogene. 2000 Feb 21;19(8):1065-71 [10713691.001]
  • [Cites] Int J Cancer. 2000 Sep 20;89(5):403-10 [11008201.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):5922-8 [11085504.001]
  • [Cites] Semin Oncol. 2001 Feb;28(1):53-67 [11254867.001]
  • [Cites] Eur J Cancer. 2001 Aug;37(12):1537-44 [11506963.001]
  • [Cites] Lab Invest. 2001 Nov;81(11):1545-51 [11706062.001]
  • [Cites] Int J Mol Med. 2002 Feb;9(2):189-96 [11786932.001]
  • [Cites] Breast Cancer Res Treat. 2002 Jul;74(1):25-31 [12150449.001]
  • [Cites] J Pathol. 2002 Oct;198(2):190-7 [12237878.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):910-9 [12569590.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1186-95 [12654426.001]
  • [Cites] Br J Surg. 2003 Sep;90(9):1093-102 [12945077.001]
  • [Cites] J Pathol. 2003 Sep;201(1):75-82 [12950019.001]
  • [Cites] Int J Cancer. 2002 May 1;99(1):35-42 [11948489.001]
  • (PMID = 16497871.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  • [Other-IDs] NLM/ PMC1860364
  •  go-up   go-down


93. Tawfik OW, Kimler BF, Davis M, Donahue JK, Persons DL, Fan F, Hagemeister S, Thomas P, Connor C, Jewell W, Fabian CJ: Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma. Histopathology; 2006 Feb;48(3):258-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma.
  • AIMS: Immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH) are both commonly used assays for evaluation of HER-2/neu status in breast cancer.
  • METHODS AND RESULTS: Two hundred and forty-seven breast cancer cases were studied.
  • [MeSH-major] Breast Neoplasms / chemistry. Image Processing, Computer-Assisted / methods. Immunohistochemistry / methods. In Situ Hybridization, Fluorescence. Receptor, ErbB-2 / analysis. Receptor, ErbB-2 / genetics
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / genetics. Adenocarcinoma, Mucinous / chemistry. Adenocarcinoma, Mucinous / genetics. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Carcinoma, Ductal, Breast / chemistry. Carcinoma, Ductal, Breast / genetics. Carcinoma, Lobular / chemistry. Carcinoma, Lobular / genetics. Carcinoma, Medullary / chemistry. Carcinoma, Medullary / genetics. Carcinoma, Squamous Cell / chemistry. Carcinoma, Squamous Cell / genetics. Female. Gene Expression Regulation, Neoplastic. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16430472.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


94. Canchola AJ, Horn-Ross PL, Purdie DM: Risk of second primary malignancies in women with papillary thyroid cancer. Am J Epidemiol; 2006 Mar 15;163(6):521-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Second malignancies in women diagnosed with thyroid cancer are of concern given the young average age at diagnosis and excellent survival.
  • Follow-up was calculated from 2 months until the diagnosis of a second primary cancer, death, loss to follow-up, or December 31, 1999, whichever occurred first.
  • The incidence of invasive breast cancer was not elevated compared with California women overall (standardized incidence ratio (SIR) = 0.9, 95% confidence interval (CI): 0.7, 1.1) or when stratified by age, race/ethnicity, follow-up, or radiation treatment.
  • An excess of in situ breast cancer (SIR = 1.6, 95% CI: 1.0, 2.4), kidney cancer (SIR = 3.9, 95% CI: 2.2, 6.3), and melanoma (SIR = 2.1, 95% CI: 1.3, 3.2) limited to the first 5 years after diagnosis was observed.
  • Women with papillary thyroid cancer are at increased risk of in situ, but not invasive, breast cancer, kidney cancer, and melanoma.
  • [MeSH-major] Adenocarcinoma, Papillary / epidemiology. Breast Neoplasms / epidemiology. Kidney Neoplasms / epidemiology. Melanoma / epidemiology. Neoplasms, Second Primary / epidemiology. Thyroid Neoplasms / epidemiology


95. Lin MC, Lomo L, Baak JP, Eng C, Ince TA, Crum CP, Mutter GL: Squamous morules are functionally inert elements of premalignant endometrial neoplasia. Mod Pathol; 2009 Feb;22(2):167-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous morules are functionally inert elements of premalignant endometrial neoplasia.
  • Squamous morules are a common component of premalignant glandular lesions that are followed by glandular, rather than squamous, carcinomas.
  • We tested the hypothesis that the appearance of glands associated with morules predicts cancer risk, and undertook molecular testing to determine the clonal and hormonal response properties of admixed squamous and glandular elements.
  • A total of 66 patients with squamous morules in an index endometrial biopsy had follow-up clinical data (average follow-up: interval 31 months, 2.5 biopsies) showing development of carcinoma in 11% (7/66) of cases.
  • The histological appearance of morule-associated glands in the index biopsy was significantly associated with this clinical outcome, with the majority (71%, 5/7) of cancer occurrences following an overtly premalignant lesion (endometrial intraepithelial neoplasia) with squamous morules.
  • Eight endometrial intraepithelial neoplasias with squamous morules were examined by immunohistochemistry for estrogen and progesterone receptors and mitotic activity (Ki-67 antigen percent stained).
  • Glandular components had abundant estrogen and progesterone receptors, and high levels of mitotic activity in all cases.
  • In sharp contrast, all squamous morules were devoid of sex hormone receptors and had undetectable or extremely low-proliferation rates.
  • When mutated, the same specific PTEN mutation was detected in squamous and glandular elements, indicating that both are of common lineage.
  • The clinical and laboratory data are consistent with a model of morule biology in which squamous morules are a hormonally incompetent subpopulation of endometrial glandular lesions.
  • Isolated morules might result from artifactual displacement from their native glandular context, or selective hormonally induced regression of the glandular but not squamous components over time.
  • Subsequent cancer risk, as promoted by estrogens, is greatest when the glandular component has the appearance of endometrial intraepithelial neoplasia.
  • Even isolated morules should be carefully followed, however, to exclude a coexisting undersampled, or occult, glandular lesion.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynecol Pathol. 2007 Apr;26(2):103-14 [17413975.001]
  • [Cites] Am J Surg Pathol. 2005 Oct;29(10):1322-9 [16160475.001]
  • [Cites] J Natl Cancer Inst. 2000 Jun 7;92(11):924-30 [10841828.001]
  • [Cites] Gynecol Oncol. 2000 Nov;79(2):169-76 [11063639.001]
  • [Cites] J Pathol. 2001 May;194(1):59-67 [11329142.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4311-4 [11389050.001]
  • [Cites] Am J Obstet Gynecol. 2002 Apr;186(4):651-7 [11967486.001]
  • [Cites] J Clin Pathol. 2002 May;55(5):326-31 [11986334.001]
  • [Cites] Gynecol Oncol. 2003 Feb;88(2):108-17 [12586588.001]
  • [Cites] Breast Cancer Res. 2003;5(2):63-8 [12631383.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):1008-13 [14984979.001]
  • [Cites] Gynecol Oncol. 1983 Feb;15(1):10-7 [6822361.001]
  • [Cites] Cancer. 1986 Jan 15;57(2):340-5 [3942966.001]
  • [Cites] Semin Diagn Pathol. 1988 May;5(2):154-71 [3041509.001]
  • [Cites] Int J Gynecol Pathol. 1995 Jul;14(3):230-4 [8600074.001]
  • [Cites] J Pathol. 1996 Nov;180(3):275-82 [8958805.001]
  • [Cites] Cancer. 1997 Jan 15;79(2):320-7 [9010105.001]
  • [Cites] Cancer Res. 1997 Sep 15;57(18):3935-40 [9307275.001]
  • [Cites] J Pathol. 1997 Aug;182(4):429-36 [9306964.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4736-8 [9354433.001]
  • [Cites] Cancer Res. 1998 Jun 15;58(12):2500-3 [9635567.001]
  • [Cites] Hum Pathol. 1998 Sep;29(9):924-31 [9744308.001]
  • [Cites] Mod Pathol. 2005 Mar;18(3):324-30 [15529181.001]
  • [Cites] Cancer. 2005 Jun 1;103(11):2304-12 [15856484.001]
  • [Cites] J Pathol. 2000 Mar;190(4):462-9 [10699996.001]
  • (PMID = 19180120.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA092301-02; United States / NCI NIH HHS / CA / R01 CA092301; United States / NCI NIH HHS / CA / R01 CA100833-01A1; United States / NCI NIH HHS / CA / R01 CA100833-05; United States / NCI NIH HHS / CA / R01-CA92301; United States / NCI NIH HHS / CA / R01 CA092301-01A1; United States / NCI NIH HHS / CA / R01 CA092301-02; United States / NCI NIH HHS / CA / R01 CA100833; United States / NCI NIH HHS / CA / R01 CA100833-03; United States / NCI NIH HHS / CA / R01 CA092301-03; United States / NCI NIH HHS / CA / CA100833-04; United States / NCI NIH HHS / CA / CA100833-03; United States / NCI NIH HHS / CA / R01 CA100833-02; United States / NCI NIH HHS / CA / CA092301-05; United States / NCI NIH HHS / CA / R01 CA092301-05; United States / NCI NIH HHS / CA / CA092301-03; United States / NCI NIH HHS / CA / R01 CA100833-04; United States / NCI NIH HHS / CA / CA100833-01A1; United States / NCI NIH HHS / CA / R01 CA092301-04; United States / NCI NIH HHS / CA / CA100833-05; United States / NCI NIH HHS / CA / CA092301-01A1; United States / NCI NIH HHS / CA / R01-CA100833; United States / NCI NIH HHS / CA / CA100833-02; United States / NCI NIH HHS / CA / CA092301-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Other-IDs] NLM/ NIHMS71886; NLM/ PMC2633489
  •  go-up   go-down


96. Liu YJ, Yan PS, Li J, Jia JF: Expression and significance of CD44s, CD44v6, and nm23 mRNA in human cancer. World J Gastroenterol; 2005 Nov 14;11(42):6601-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To investigate the relationship between the expression levels of nm23 mRNA, CD44s, and CD44v6, and oncogenesis, development and metastasis of human gastric adenocarcinoma, colorectal adenocarcinoma, intraductal carcinoma of breast, and lung cancer.
  • METHODS: Using tissue microarray by immuhistochemical (IHC) staining and in situ hybridization (ISH), we examined the expression levels of nm23 mRNA, CD44s, and CD44v6 in 62 specimens of human gastric adenocarcinoma and 62 specimens of colorectal adenocarcinoma; the expression of CD44s and CD44v6 in 120 specimens of intraductal carcinoma of breast and 20 specimens of normal breast tissue; the expression of nm23 mRNA in 72 specimens of human lung cancer and 23 specimens of normal tissue adjacent to cancer.
  • RESULTS: The expression of nm23 mRNA in the tissues of gastric and colorectal adenocarcinoma was not significantly different from that in the normal tissues adjacent to cancer (P>0.05), and was not associated with the invasion of tumor and the pathology grade of adenocarcinoma (P>0.05).
  • However, the expression of nm23 mRNA was correlated negatively to the lymph node metastasis of gastric and colorectal adenocarcinoma (r = -0.49, P<0.01; r = -4.93, P<0.01).
  • The expression of CD44s in the tissues of gastric and colorectal adenocarcinoma was significantly different from that in the normal tissues adjacent to cancer (P<0.05; P<0.01).
  • CD44v6 was expressed in the tissues of gastric and colorectal adenocarcinoma only, the expression of CD44v6 was significantly associated with the lymph node metastasis, invasion and pathological grade of the tumor (r = 0.47, P<0.01; r = 5.04, P<0.01).
  • CD44s and CD44v6 were expressed in intraductal carcinoma of breast, the expression of CD44s and CD44v6 was significantly associated with lymph node metastases and invasion (P<0.01).
  • However, neither of them was expressed in the normal breast tissue.
  • In addition, the expression of CD44v6 was closely related to the degree of cell differentiation of intraductal carcinoma of breast (c2 = 5.68, P<0.05).
  • [MeSH-minor] Antigens, Neoplasm / genetics. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Breast Neoplasms / genetics. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Colorectal Neoplasms / genetics. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. Female. Humans. Immunohistochemistry. In Situ Hybridization. Lung Neoplasms / genetics. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. NM23 Nucleoside Diphosphate Kinases. Neoplasm Metastasis. Nucleoside-Diphosphate Kinase. Protein Array Analysis. Stomach Neoplasms / genetics. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16425351.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CD44v6 antigen; 0 / Glycoproteins; 0 / NM23 Nucleoside Diphosphate Kinases; 0 / RNA, Messenger; EC 2.7.4.6 / NME1 protein, human; EC 2.7.4.6 / Nucleoside-Diphosphate Kinase
  • [Other-IDs] NLM/ PMC4355751
  •  go-up   go-down


97. Shah SS, Adelson M, Mazur MT: Adenocarcinoma in situ arising in vulvar papillary hidradenoma: report of 2 cases. Int J Gynecol Pathol; 2008 Jul;27(3):453-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma in situ arising in vulvar papillary hidradenoma: report of 2 cases.
  • Adenocarcinoma in situ rarely occurs in vulvar papillary hidradenoma.
  • We encountered 2 cases of adenocarcinoma in situ arising in a papillary hidradenoma of the vulva.
  • On microscopic examination, the tumors showed focal features of benign hidradenoma at the periphery with transitions into areas of increasing cytologic atypia that fulfilled criteria for adenocarcinoma in situ similar to that seen in the breast.
  • There was no evidence of benign ectopic breast tissue within or adjacent to the neoplasms.
  • The fact that these tumors displayed morphologic and immunohistochemical features that resembled ductal carcinoma in situ of the breast demonstrates the close homology between papillary hidradenoma and breast epithelium.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma, Sweat Gland / pathology. Carcinoma in Situ / pathology. Vulvar Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580327.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Gadre SA, Perkins GH, Sahin AA, Sneige N, Deavers MT, Middleton LP: Neovascularization in mucinous ductal carcinoma in situ suggests an alternative pathway for invasion. Histopathology; 2008 Nov;53(5):545-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neovascularization in mucinous ductal carcinoma in situ suggests an alternative pathway for invasion.
  • AIMS: Ductal carcinoma in situ (DCIS) associated with invasive mucinous carcinoma (IMC) has not been well characterized.
  • The aim was to characterize mucinous DCIS (mDCIS) of the breast and to describe, to our knowledge for the first time, neovascularization in mucin.
  • Anderson Cancer Center, whose diagnosis fulfilled the criteria of IMC or DCIS with mucin production.
  • When identified on core needle biopsy, the presence of vascularized mucin should not be used alone to discriminate between invasive and in situ carcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / blood supply. Carcinoma, Intraductal, Noninfiltrating / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18983463.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Mucins; 0 / Trans-Activators; 0 / Vascular Endothelial Growth Factor A; 156560-97-3 / Cdx-2-3 protein
  •  go-up   go-down


99. Gu M, Ghafari S, Zhao M: Fluorescence in situ hybridization for HER-2/neu amplification of breast carcinoma in archival fine needle aspiration biopsy specimens. Acta Cytol; 2005 Sep-Oct;49(5):471-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorescence in situ hybridization for HER-2/neu amplification of breast carcinoma in archival fine needle aspiration biopsy specimens.
  • OBJECTIVE: To assess the usefulness of fluorescence in situ hybridization (FISH) for HER-2/neu amplification of breast carcinoma in archival fine needle aspiration biopsy (FNAB) specimens.
  • RESULTS: FISH was performed on 41 surgical specimens of breast carcinoma.
  • Thirteen patients had prior FNABs that were positive for adenocarcinoma.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma / diagnosis. Gene Amplification / genetics. Genes, erbB-2 / genetics. In Situ Hybridization, Fluorescence / methods. Receptor, ErbB-2 / genetics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16334021.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab
  •  go-up   go-down


100. Soini Y, Tommola S, Helin H, Martikainen P: Claudins 1, 3, 4 and 5 in gastric carcinoma, loss of claudin expression associates with the diffuse subtype. Virchows Arch; 2006 Jan;448(1):52-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Membrane Proteins / biosynthesis. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology
  • [MeSH-minor] Apoptosis / physiology. Biomarkers, Tumor / analysis. Cadherins / biosynthesis. Cell Proliferation. Humans. Immunohistochemistry. In Situ Nick-End Labeling. Ki-67 Antigen / biosynthesis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2003 Apr 3;22(13):2021-33 [12673207.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1745-54 [12000726.001]
  • [Cites] Breast Cancer Res. 2005;7(2):R296-305 [15743508.001]
  • [Cites] J Cell Biol. 1992 Apr;117(2):415-25 [1373144.001]
  • [Cites] J Am Soc Nephrol. 2002 Apr;13(4):875-86 [11912246.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6265-71 [14559813.001]
  • [Cites] J Cell Biol. 2000 Apr 3;149(1):13-6 [10747082.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Curr Opin Cell Biol. 2002 Oct;14(5):531-6 [12231346.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1620-6 [12459629.001]
  • [Cites] Cancer Res. 1993 Apr 1;53(7):1690-5 [8453643.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):678-84 [11522752.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7878-81 [11691807.001]
  • [Cites] Hum Pathol. 2004 Dec;35(12):1531-6 [15619213.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1627-33 [15111309.001]
  • [Cites] J Cell Biol. 1988 Oct;107(4):1575-87 [3049625.001]
  • [Cites] J Cell Sci. 2004 May 15;117(Pt 12):2435-47 [15159449.001]
  • [Cites] Gastroenterology. 2001 Feb;120(2):411-22 [11159882.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2000 Aug;279(2):G250-4 [10915631.001]
  • [Cites] Kidney Int. 2002 Aug;62(2):476-87 [12110008.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6281-7 [11103784.001]
  • [Cites] J Mol Cell Cardiol. 2005 Feb;38(2):323-32 [15698839.001]
  • (PMID = 16220299.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Ki-67 Antigen; 0 / Membrane Proteins
  •  go-up   go-down






Advertisement